TR201808812T4 - Fenil derivesi. - Google Patents
Fenil derivesi. Download PDFInfo
- Publication number
- TR201808812T4 TR201808812T4 TR2018/08812T TR201808812T TR201808812T4 TR 201808812 T4 TR201808812 T4 TR 201808812T4 TR 2018/08812 T TR2018/08812 T TR 2018/08812T TR 201808812 T TR201808812 T TR 201808812T TR 201808812 T4 TR201808812 T4 TR 201808812T4
- Authority
- TR
- Turkey
- Prior art keywords
- group
- hydroxy
- phenoxy
- trifluoromethyl
- acid
- Prior art date
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title claims description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 119
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 125000005843 halogen group Chemical group 0.000 claims abstract description 19
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 12
- 230000004761 fibrosis Effects 0.000 claims abstract description 12
- 101710155462 Sphingosine 1-phosphate receptor 2 Proteins 0.000 claims abstract description 11
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 claims abstract description 11
- 230000002792 vascular Effects 0.000 claims abstract description 11
- 230000001404 mediated effect Effects 0.000 claims abstract description 9
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 8
- -1 3-cyclohexyl-3-hydroxy-1-pyrrolidinyl Chemical group 0.000 claims description 106
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 16
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 15
- 150000001204 N-oxides Chemical class 0.000 claims description 14
- 239000012453 solvate Substances 0.000 claims description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 8
- 206010046996 Varicose vein Diseases 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 208000027185 varicose disease Diseases 0.000 claims description 8
- 208000007232 portal hypertension Diseases 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 230000002455 vasospastic effect Effects 0.000 claims description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 208000002249 Diabetes Complications Diseases 0.000 claims description 4
- 206010012655 Diabetic complications Diseases 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010019663 Hepatic failure Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- 206010052428 Wound Diseases 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 208000021328 arterial occlusion Diseases 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentane carboxylic acid Natural products OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 208000007903 liver failure Diseases 0.000 claims description 4
- 231100000835 liver failure Toxicity 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- XGXAWZZFINPDDM-UHFFFAOYSA-N 1-[4-[3-[(3-cyclohexyl-3-hydroxypyrrolidine-1-carbonyl)amino]-5-(trifluoromethyl)phenoxy]phenyl]cyclobutane-1-carboxylic acid Chemical compound C=1C=C(OC=2C=C(C=C(NC(=O)N3CC(O)(CC3)C3CCCCC3)C=2)C(F)(F)F)C=CC=1C1(C(=O)O)CCC1 XGXAWZZFINPDDM-UHFFFAOYSA-N 0.000 claims description 3
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- CNQKALVJVAIPQJ-UHFFFAOYSA-N 4-cyclopentyl-N-[3-[4-(ethylsulfonylcarbamoyl)phenoxy]-5-(trifluoromethyl)phenyl]-4-hydroxypiperidine-1-carboxamide Chemical compound C1(CCCC1)C1(CCN(CC1)C(=O)NC1=CC(=CC(=C1)C(F)(F)F)OC1=CC=C(C=C1)C(NS(=O)(=O)CC)=O)O CNQKALVJVAIPQJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010003445 Ascites Diseases 0.000 claims description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010041660 Splenomegaly Diseases 0.000 claims description 2
- 206010056091 Varices oesophageal Diseases 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 208000034158 bleeding Diseases 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 208000024170 esophageal varices Diseases 0.000 claims description 2
- 201000010120 esophageal varix Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- RHCHKAVZFUJQNR-UHFFFAOYSA-N 2-[3-[3-[(3-cyclohexyl-3-hydroxypyrrolidine-1-carbonyl)amino]-5-(trifluoromethyl)phenoxy]phenyl]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=CC=CC(OC=2C=C(C=C(NC(=O)N3CC(O)(CC3)C3CCCCC3)C=2)C(F)(F)F)=C1 RHCHKAVZFUJQNR-UHFFFAOYSA-N 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- SKSGOBXVBLIWLF-UHFFFAOYSA-N 1-[4-[3-[(3-cyclohexyl-3-hydroxypyrrolidine-1-carbonyl)amino]-5-(trifluoromethyl)phenoxy]phenoxy]cyclopropane-1-carboxylic acid Chemical compound C=1C=C(OC=2C=C(C=C(NC(=O)N3CC(O)(CC3)C3CCCCC3)C=2)C(F)(F)F)C=CC=1OC1(C(=O)O)CC1 SKSGOBXVBLIWLF-UHFFFAOYSA-N 0.000 claims 1
- IQQXWLGPIQHEDI-UHFFFAOYSA-N 1-[4-[3-[(3-cyclohexyl-3-hydroxypyrrolidine-1-carbonyl)amino]-5-(trifluoromethyl)phenoxy]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C=C(OC=2C=C(C=C(NC(=O)N3CC(O)(CC3)C3CCCCC3)C=2)C(F)(F)F)C=CC=1C1(C(=O)O)CC1 IQQXWLGPIQHEDI-UHFFFAOYSA-N 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 17
- 230000003042 antagnostic effect Effects 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 13
- 125000001188 haloalkyl group Chemical group 0.000 abstract description 6
- 238000006467 substitution reaction Methods 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 101100236683 Homo sapiens MBTPS1 gene Proteins 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000002904 solvent Substances 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 239000000203 mixture Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 238000009472 formulation Methods 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 238000010511 deprotection reaction Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 10
- 230000000069 prophylactic effect Effects 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000704 physical effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000002997 ophthalmic solution Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 4
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 4
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- 101000693262 Homo sapiens Sphingosine 1-phosphate receptor 2 Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 102000003938 Thromboxane Receptors Human genes 0.000 description 4
- 108090000300 Thromboxane Receptors Proteins 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 4
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 4
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- DTHHUAXKOMWYBI-UHFFFAOYSA-N oxadiazolidine Chemical compound C1CONN1 DTHHUAXKOMWYBI-UHFFFAOYSA-N 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical group ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 3
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 3
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 3
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 235000011116 calcium hydroxide Nutrition 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 102000054996 human S1PR2 Human genes 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229960004584 methylprednisolone Drugs 0.000 description 3
- 150000002823 nitrates Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229940060184 oil ingredients Drugs 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- OQJVXNHMUWQQEW-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazine Chemical compound C1CNC=CN1 OQJVXNHMUWQQEW-UHFFFAOYSA-N 0.000 description 2
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 description 2
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 2
- UUZJJNBYJDFQHL-UHFFFAOYSA-N 1,2,3-triazolidine Chemical compound C1CNNN1 UUZJJNBYJDFQHL-UHFFFAOYSA-N 0.000 description 2
- AGSHYIAAUGKFEA-UHFFFAOYSA-N 1,2,5-oxadiazolidine Chemical compound C1CNON1 AGSHYIAAUGKFEA-UHFFFAOYSA-N 0.000 description 2
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 2
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical compound N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 description 2
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 2
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 2
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- SCEIUGQQBYRBPP-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-azepine Chemical compound C1CCC=CNC1 SCEIUGQQBYRBPP-UHFFFAOYSA-N 0.000 description 2
- YYVKQFQZKSLYFN-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-diazepine Chemical compound C1CNNC=CC1 YYVKQFQZKSLYFN-UHFFFAOYSA-N 0.000 description 2
- GLCYMVDVOVIDBB-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxadiazepine Chemical compound C1CC=CONN1 GLCYMVDVOVIDBB-UHFFFAOYSA-N 0.000 description 2
- ABQOPHYTASMWLA-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxazepine Chemical compound C1CNOC=CC1 ABQOPHYTASMWLA-UHFFFAOYSA-N 0.000 description 2
- WHUAPUGLAGYTQS-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiadiazepine Chemical compound C1CC=CSNN1 WHUAPUGLAGYTQS-UHFFFAOYSA-N 0.000 description 2
- IFPKIMVCYSSDDJ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiazepine Chemical compound C1CNSC=CC1 IFPKIMVCYSSDDJ-UHFFFAOYSA-N 0.000 description 2
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 2
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 2
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 2
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 2
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 2
- BEWVAZNECYSPMT-UHFFFAOYSA-N 2,3-dihydro-1h-azepine Chemical compound C1CC=CC=CN1 BEWVAZNECYSPMT-UHFFFAOYSA-N 0.000 description 2
- QHYXWSXPPUTDRA-UHFFFAOYSA-N 2,3-dihydro-1h-diazepine Chemical compound C1NNC=CC=C1 QHYXWSXPPUTDRA-UHFFFAOYSA-N 0.000 description 2
- IZEOXCXHDBQQAP-UHFFFAOYSA-N 2,3-dihydrothiazepine Chemical compound C1NSC=CC=C1 IZEOXCXHDBQQAP-UHFFFAOYSA-N 0.000 description 2
- PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 description 2
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 2
- NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical compound C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000012661 PARP inhibitor Substances 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940083712 aldosterone antagonist Drugs 0.000 description 2
- 239000002170 aldosterone antagonist Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 2
- 229960003556 aminophylline Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- 150000001555 benzenes Chemical class 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 2
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229940066493 expectorants Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000382 optic material Substances 0.000 description 2
- OTLYTKRAADUASA-UHFFFAOYSA-N oxadiazepane Chemical compound C1CCONNC1 OTLYTKRAADUASA-UHFFFAOYSA-N 0.000 description 2
- XCRJTRCPEJKXLR-UHFFFAOYSA-N oxadiazinane Chemical compound C1CNNOC1 XCRJTRCPEJKXLR-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 239000003590 rho kinase inhibitor Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- KHVCOYGKHDJPBZ-WDCZJNDASA-N tetrahydrooxazine Chemical compound OC[C@H]1ONC[C@@H](O)[C@@H]1O KHVCOYGKHDJPBZ-WDCZJNDASA-N 0.000 description 2
- ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- TVQOEGVBMRCMFR-UHFFFAOYSA-N thiadiazinane Chemical compound C1CNNSC1 TVQOEGVBMRCMFR-UHFFFAOYSA-N 0.000 description 2
- PGAZQSBUJDVGIX-UHFFFAOYSA-N thiazepane Chemical compound C1CCNSCC1 PGAZQSBUJDVGIX-UHFFFAOYSA-N 0.000 description 2
- AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical compound C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- SFZVXTJDDOYGIS-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)-methylazanium;chloride Chemical compound Cl.CNC(CS)C(O)=O SFZVXTJDDOYGIS-UHFFFAOYSA-N 0.000 description 1
- IOVGROKTTNBUGK-SJKOYZFVSA-N (1S,2R)-ritodrine Chemical compound N([C@H](C)[C@@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJKOYZFVSA-N 0.000 description 1
- UHSXRTHJCJGEKG-UQKRIMTDSA-N (1s)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-6,7-diol;chloride Chemical compound Cl.COC1=C(OC)C(OC)=CC(C[C@H]2C3=CC(O)=C(O)C=C3CCN2)=C1 UHSXRTHJCJGEKG-UQKRIMTDSA-N 0.000 description 1
- CEMAWMOMDPGJMB-CYBMUJFWSA-N (2r)-1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-CYBMUJFWSA-N 0.000 description 1
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 description 1
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- MYZDPUZXMFCPMU-LRIWMWCYSA-N (6r,8s,9r,10s,11s,13s,14s,17r)-2-bromo-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1C(Br)=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@@H](F)C2=C1 MYZDPUZXMFCPMU-LRIWMWCYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 1
- FWLKKPKZQYVAFR-LVEZLNDCSA-N (e)-but-2-enedioic acid;1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 FWLKKPKZQYVAFR-LVEZLNDCSA-N 0.000 description 1
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- YUIOPHXTILULQC-UHFFFAOYSA-N 1,4-Dithiane-2,5-diol Chemical compound OC1CSC(O)CS1 YUIOPHXTILULQC-UHFFFAOYSA-N 0.000 description 1
- GFJKASVFAWFUNI-UHFFFAOYSA-N 1-chloro-3,5-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC([N+]([O-])=O)=C1 GFJKASVFAWFUNI-UHFFFAOYSA-N 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- SOHIYESEPVZKHS-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxepine Chemical compound C1CCC=COC1 SOHIYESEPVZKHS-UHFFFAOYSA-N 0.000 description 1
- VRKPANGTGANDRQ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiepine Chemical compound C1CCC=CSC1 VRKPANGTGANDRQ-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- MMYHKAAYOKCSJP-UHFFFAOYSA-N 2-[4-[3-[[4-hydroxy-4-(2-methylpropyl)piperidine-1-carbonyl]amino]-5-(trifluoromethyl)benzoyl]oxyphenyl]-2-methylpropanoic acid Chemical compound C1CC(CC(C)C)(O)CCN1C(=O)NC1=CC(C(=O)OC=2C=CC(=CC=2)C(C)(C)C(O)=O)=CC(C(F)(F)F)=C1 MMYHKAAYOKCSJP-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- KKZUMAMOMRDVKA-UHFFFAOYSA-N 2-chloropropane Chemical group [CH2]C(C)Cl KKZUMAMOMRDVKA-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 description 1
- LGGKPLUYXWEXNG-UHFFFAOYSA-N 3-[[4-hydroxy-4-(2-methylpropyl)piperidine-1-carbonyl]amino]-5-(trifluoromethyl)benzoic acid Chemical compound OC1(CCN(CC1)C(=O)NC=1C=C(C(=O)O)C=C(C1)C(F)(F)F)CC(C)C LGGKPLUYXWEXNG-UHFFFAOYSA-N 0.000 description 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- UUKSWUYLKRUYEK-UHFFFAOYSA-N 4-(2-methylpropyl)piperidin-4-ol Chemical compound CC(C)CC1(O)CCNCC1 UUKSWUYLKRUYEK-UHFFFAOYSA-N 0.000 description 1
- ZOLBALGTFCCTJF-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC=C(O)C(O)=C1.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 ZOLBALGTFCCTJF-UHFFFAOYSA-N 0.000 description 1
- IGOSMAABRUZEIQ-UHFFFAOYSA-N 4-cyclopentyl-4-hydroxy-n-[3-[4-(methylsulfonylcarbamoyl)phenoxy]-5-(trifluoromethyl)phenyl]piperidine-1-carboxamide Chemical compound C1=CC(C(=O)NS(=O)(=O)C)=CC=C1OC1=CC(NC(=O)N2CCC(O)(CC2)C2CCCC2)=CC(C(F)(F)F)=C1 IGOSMAABRUZEIQ-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
- AWRLZJJDHWCYKN-UHFFFAOYSA-N 5-bromo-2-ethoxy-3-nitropyridine Chemical compound CCOC1=NC=C(Br)C=C1[N+]([O-])=O AWRLZJJDHWCYKN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- RJPWESHPIMRNNM-UHFFFAOYSA-N Bunitrolol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)COC1=CC=CC=C1C#N RJPWESHPIMRNNM-UHFFFAOYSA-N 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 description 1
- VKJHTUVLJYWAEY-UHFFFAOYSA-N Celiprolol hydrochloride Chemical compound Cl.CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 VKJHTUVLJYWAEY-UHFFFAOYSA-N 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FDJCVHVKXFIEPJ-JCNFZFLDSA-N Delapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 FDJCVHVKXFIEPJ-JCNFZFLDSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 206010051010 Duodenal varices Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010051012 Gastric varices Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MMCDXJOMPMIKGP-UHFFFAOYSA-N Mabuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 MMCDXJOMPMIKGP-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 101000693261 Mus musculus Sphingosine 1-phosphate receptor 2 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
- 102100026476 Prostacyclin receptor Human genes 0.000 description 1
- 101710170814 Prostacyclin receptor Proteins 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102000000471 Prostaglandin F receptors Human genes 0.000 description 1
- 108050008995 Prostaglandin F receptors Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical compound N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NFQIAEMCQGTTIR-UHFFFAOYSA-N Repirinast Chemical compound C12=CC=C(C)C(C)=C2NC(=O)C2=C1OC(C(=O)OCCC(C)C)=CC2=O NFQIAEMCQGTTIR-UHFFFAOYSA-N 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 108700008242 S-(2-chloro-1,1,2-trifluoroethyl)glutathione Proteins 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 229920002536 Scavenger resin Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N Seratrodast Chemical compound O=C1C(C)=C(C)C(=O)C(C(CCCCCC(O)=O)C=2C=CC=CC=2)=C1C ZBVKEHDGYSLCCC-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 206010050207 Skin fibrosis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- XQTARQNQIVVBRX-UHFFFAOYSA-N Tazanolast Chemical compound CCCCOC(=O)C(=O)NC1=CC=CC(C2=NNN=N2)=C1 XQTARQNQIVVBRX-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- RSLNRVYIRDVHLY-UHFFFAOYSA-N Tulobuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC=CC=C1Cl RSLNRVYIRDVHLY-UHFFFAOYSA-N 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- MKFFGUZYVNDHIH-UHFFFAOYSA-N [2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]-propan-2-ylazanium;sulfate Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)NCC(O)C1=CC(O)=CC(O)=C1 MKFFGUZYVNDHIH-UHFFFAOYSA-N 0.000 description 1
- QQPGGBNMTNDKEY-UHFFFAOYSA-N [2-butyl-5-chloro-3-[[4-[2-(2-trityltetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NN(N=N2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=C1 QQPGGBNMTNDKEY-UHFFFAOYSA-N 0.000 description 1
- RYVJQEZJUFRANT-UHFFFAOYSA-N [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 RYVJQEZJUFRANT-UHFFFAOYSA-N 0.000 description 1
- DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 1
- DMEPDNFRHUGNPT-UHFFFAOYSA-N [5-(diethylamino)-2-methylpent-3-yn-2-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C=1C=CC=CC=1C(O)(C(=O)OC(C)(C)C#CCN(CC)CC)C1CCCCC1 DMEPDNFRHUGNPT-UHFFFAOYSA-N 0.000 description 1
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 1
- JLCHNBRGUPQWKF-UHFFFAOYSA-J [OH-].[C+4].[OH-].[OH-].[OH-] Chemical compound [OH-].[C+4].[OH-].[OH-].[OH-] JLCHNBRGUPQWKF-UHFFFAOYSA-J 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- YDIQJONNFLVNGD-FPMRONRSSA-N ac1l3tts Chemical compound C([C@]12[C@H]3C[C@H]3[C@@H]3[C@]1(C)CC[C@@H]1[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]31)C(=O)OC)CC(=O)O2 YDIQJONNFLVNGD-FPMRONRSSA-N 0.000 description 1
- KTUFKADDDORSSI-UHFFFAOYSA-N acebutolol hydrochloride Chemical compound Cl.CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 KTUFKADDDORSSI-UHFFFAOYSA-N 0.000 description 1
- 229960003830 acebutolol hydrochloride Drugs 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229960000852 alprenolol hydrochloride Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- BHIAIPWSVYSKJS-UHFFFAOYSA-N arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 description 1
- 229950010731 arotinolol Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- TYNZVWXDLOJTIM-QQFWICJTSA-N astromycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O[C@@H]1[C@H](N(C)C(=O)CN)[C@@H](OC)[C@@H](O)[C@H](N)[C@H]1O[C@@H]1[C@H](N)CC[C@@H]([C@H](C)N)O1 TYNZVWXDLOJTIM-QQFWICJTSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960004335 azelastine hydrochloride Drugs 0.000 description 1
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
- 229960003619 benazepril hydrochloride Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WLTKZBRCTCWYQI-UHFFFAOYSA-N benzyl 2-(3-hydroxyphenyl)-2-methylpropanoate Chemical compound OC=1C=C(C=CC1)C(C(=O)OCC1=CC=CC=C1)(C)C WLTKZBRCTCWYQI-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 1
- 229960002071 bepotastine Drugs 0.000 description 1
- JXBBWYGMTNAYNM-UHFFFAOYSA-N bepridil hydrochloride Chemical compound [H+].[Cl-].C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 JXBBWYGMTNAYNM-UHFFFAOYSA-N 0.000 description 1
- 229960004156 bepridil hydrochloride Drugs 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- 229960003588 bevantolol Drugs 0.000 description 1
- FJTKCFSPYUMXJB-UHFFFAOYSA-N bevantolol hydrochloride Chemical compound [Cl-].C1=C(OC)C(OC)=CC=C1CC[NH2+]CC(O)COC1=CC=CC(C)=C1 FJTKCFSPYUMXJB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960005400 bisoprolol fumarate Drugs 0.000 description 1
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960002335 bromhexine hydrochloride Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229950009385 bufetolol Drugs 0.000 description 1
- AKLNLVOZXMQGSI-UHFFFAOYSA-N bufetolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1OCC1OCCC1 AKLNLVOZXMQGSI-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229950008581 bunitrolol Drugs 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 229960005057 canrenone Drugs 0.000 description 1
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
- 229960002165 carteolol hydrochloride Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- DASYMCLQENWCJG-XUKDPADISA-N cefetamet pivoxil Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DASYMCLQENWCJG-XUKDPADISA-N 0.000 description 1
- 229950000726 cefetamet pivoxil Drugs 0.000 description 1
- 229960000534 cefuroxime sodium Drugs 0.000 description 1
- 229960000384 celiprolol hydrochloride Drugs 0.000 description 1
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- OPXKTCUYRHXSBK-UHFFFAOYSA-N clenbuterol hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 OPXKTCUYRHXSBK-UHFFFAOYSA-N 0.000 description 1
- 229960001399 clenbuterol hydrochloride Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000008473 connective tissue growth Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- HWEQKSVYKBUIIK-UHFFFAOYSA-N cyclobuta-1,3-diene Chemical compound C1=CC=C1 HWEQKSVYKBUIIK-UHFFFAOYSA-N 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229950000812 dexamethasone palmitate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- UDRAWOMTCXBODN-UHFFFAOYSA-N dichloromethane methanol Chemical compound ClCCl.CO.ClCCl.CO UDRAWOMTCXBODN-UHFFFAOYSA-N 0.000 description 1
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
- 229960005081 diclofenamide Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 1
- 229960001079 dilazep Drugs 0.000 description 1
- VILIWRRWAWKXRW-UHFFFAOYSA-N dilazep dihydrochloride Chemical compound [Cl-].[Cl-].COC1=C(OC)C(OC)=CC(C(=O)OCCC[NH+]2CC[NH+](CCCOC(=O)C=3C=C(OC)C(OC)=C(OC)C=3)CCC2)=C1 VILIWRRWAWKXRW-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- PWTCIBWRMQFJBC-ZEMKZVSASA-N domitroban Chemical compound N([C@H]1[C@H]2CC[C@H](C2)[C@@H]1C\C=C/CCCC(=O)O)S(=O)(=O)C1=CC=CC=C1 PWTCIBWRMQFJBC-ZEMKZVSASA-N 0.000 description 1
- 229950010759 domitroban Drugs 0.000 description 1
- RYBJORHCUPVNMB-UHFFFAOYSA-N dopexamine Chemical compound C1=C(O)C(O)=CC=C1CCNCCCCCCNCCC1=CC=CC=C1 RYBJORHCUPVNMB-UHFFFAOYSA-N 0.000 description 1
- 229960001857 dopexamine Drugs 0.000 description 1
- 229960004483 doxofylline Drugs 0.000 description 1
- HWXIGFIVGWUZAO-UHFFFAOYSA-N doxofylline Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1OCCO1 HWXIGFIVGWUZAO-UHFFFAOYSA-N 0.000 description 1
- 229960004845 drospirenone Drugs 0.000 description 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 229960000325 emedastine Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229960002548 epinastine hydrochloride Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 229960003013 epoprostenol sodium Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 description 1
- 229940031005 ethyl cysteine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 1
- 229960002435 fasudil Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960001037 fenoterol hydrobromide Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229950005583 flutropium Drugs 0.000 description 1
- OATDVDIMNNZTEY-DAXLTYESSA-N flutropium Chemical compound C[N@@+]1(CCF)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 OATDVDIMNNZTEY-DAXLTYESSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960000193 formoterol fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- GTDCHGNGVGRHQY-UHFFFAOYSA-N hexoprenaline sulfate Chemical compound [O-]S([O-])(=O)=O.C=1C=C(O)C(O)=CC=1C(O)C[NH2+]CCCCCC[NH2+]CC(O)C1=CC=C(O)C(O)=C1 GTDCHGNGVGRHQY-UHFFFAOYSA-N 0.000 description 1
- 229960000246 hexoprenaline sulfate Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 1
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 229960003409 imidapril hydrochloride Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- KFZAUHNPPZCSCR-UHFFFAOYSA-N iron zinc Chemical compound [Fe].[Zn] KFZAUHNPPZCSCR-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940018435 isoproterenol sulfate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- CMUHZRATLMUDJI-UHFFFAOYSA-N methyl 2h-pyridine-1-carboxylate Chemical compound COC(=O)N1CC=CC=C1 CMUHZRATLMUDJI-UHFFFAOYSA-N 0.000 description 1
- GMGZRXWZOZSBED-UHFFFAOYSA-N methyl 3-nitro-5-(trifluoromethyl)benzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1 GMGZRXWZOZSBED-UHFFFAOYSA-N 0.000 description 1
- LZULAZTXJLWELL-UHFFFAOYSA-N methyl hex-5-ynoate Chemical compound COC(=O)CCCC#C LZULAZTXJLWELL-UHFFFAOYSA-N 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
- 229960001300 metoprolol tartrate Drugs 0.000 description 1
- 229960004465 metyrapone Drugs 0.000 description 1
- FJLBFSROUSIWMA-UHFFFAOYSA-N metyrapone Chemical compound C=1C=CN=CC=1C(C)(C)C(=O)C1=CC=CN=C1 FJLBFSROUSIWMA-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 229960004832 netilmicin sulfate Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229950000754 nipradilol Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- RYDICHIKLKVOEJ-UHFFFAOYSA-N oxadiazepine Chemical compound O1C=CC=CN=N1 RYDICHIKLKVOEJ-UHFFFAOYSA-N 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- 229960002698 oxatomide Drugs 0.000 description 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 1
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- SHZKQBHERIJWAO-AATRIKPKSA-N ozagrel Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1CN1C=NC=C1 SHZKQBHERIJWAO-AATRIKPKSA-N 0.000 description 1
- 229950003837 ozagrel Drugs 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 229960000865 paramethasone acetate Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960004811 pemirolast potassium Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
- 229960003929 perindopril erbumine Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960000206 potassium canrenoate Drugs 0.000 description 1
- JTZQCHFUGHIPDF-RYVBEKKQSA-M potassium canrenoate Chemical compound [K+].O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC([O-])=O)[C@@H]4[C@@H]3C=CC2=C1 JTZQCHFUGHIPDF-RYVBEKKQSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- FKKAEMQFOIDZNY-CODXZCKSSA-M prednisolone sodium succinate Chemical compound [Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 FKKAEMQFOIDZNY-CODXZCKSSA-M 0.000 description 1
- 229960002176 prednisolone sodium succinate Drugs 0.000 description 1
- 229960004259 prednisolone tebutate Drugs 0.000 description 1
- 229960002789 procaterol hydrochloride Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960003042 quinapril hydrochloride Drugs 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- 229950004496 ramatroban Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 229950009147 repirinast Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229960000720 ritodrine hydrochloride Drugs 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229960003090 seratrodast Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- BGXXYHIWOXFRLF-UHFFFAOYSA-M sodium;2-(imidazol-1-ylmethyl)-4,5-dihydro-1-benzothiophene-6-carboxylate Chemical compound [Na+].C=1C=2CCC(C(=O)[O-])=CC=2SC=1CN1C=CN=C1 BGXXYHIWOXFRLF-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 108010035597 sphingosine kinase Proteins 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229950011558 tazanolast Drugs 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229950000334 temiverine Drugs 0.000 description 1
- 229960004084 temocapril Drugs 0.000 description 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- RWXZKKKYLRFREK-UHFFFAOYSA-N thiadiazepane Chemical compound C1CCSNNC1 RWXZKKKYLRFREK-UHFFFAOYSA-N 0.000 description 1
- BXVYJQULAWJPSR-UHFFFAOYSA-N thiadiazepine Chemical group S1C=CC=CN=N1 BXVYJQULAWJPSR-UHFFFAOYSA-N 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 239000003768 thromboxane synthase inhibitor Substances 0.000 description 1
- 229950008411 tilisolol Drugs 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical class C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- IQKAWAUTOKVMLE-ZSESPEEFSA-M treprostinil sodium Chemical compound [Na+].C1=CC=C(OCC([O-])=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 IQKAWAUTOKVMLE-ZSESPEEFSA-M 0.000 description 1
- 229960001726 treprostinil sodium Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960004320 triamcinolone diacetate Drugs 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 229960001177 trimetazidine Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229960004846 tulobuterol hydrochloride Drugs 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 description 1
- 229960000438 udenafil Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 229960000881 verapamil hydrochloride Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
Abstract
Mevcut buluşun bir amacı, vasküler daralma, fibrozis ve respiratuar hastalıktan kaynaklanan bir hastalık gibi S1P 2 aracılı bir hastalığın terapisine yönelik faydalı bir ilacın geliştirilmesi amacıyla güçlü insan S1P 2 antagonistik aktiviteye sahip bir bileşiği sağlamaktır. Tüm sembollerin, spesifikasyonda açıklanan ile aynı anlama sahip olduğu genel formül (I) ile temsil edilen bileşik, belirli sübstitüsyon bölgelerinde bir halojen atomuna veya haloalkil grubuna ve bir fenoksi grubuna sahiptir ve bu nedenle güçlü insan S1P 2 antagonistik aktivitesine sahiptir. Bu nedenle bileşik, vasküler daralma, fibrozis ve respiratuar hastalıktan kaynaklanan bir hastalık gibi S1P 2 aracılı bir hastalığa yönelik terapötik bir ajan olabilir.
Description
TARIFNAME
FENIL DERIVESI
TEKNIK SAHA
Mevcut bulus, genel formül (I) ile temsil edilen bir bilesik:
511,361; '5
Burada tüm semboller, asagida açiklanan ile ayni anlama sahiptir ve bir tuzu, solvati
veya N-oksidi (buradan sonra bazen mevcut bilesik olarak kisaltilir) ile ilgilidir.
ALTYAPI TEKNIGI
bundan böyle bazen 81 P olarak kisaltilacaktir] sifingolipidlerin metabolik döngüsü veya
salgilayici sifingosin kinazlarin hücre içi eylemi olarak sentetize edilen bir lipittir. Bu
düsünülür.
S1P reseptörleri arasindan S reseptörleri bakimindan,
mRNA'sinin güçlü ifadesinin kalp, akciger, mide ve Ince bagirsak dokularinda
onaylandigi ve koroner arteriyosklerosiz için model olan karotid balon yaralanmasinin
deney farelerindeki normal intimal hücrelerinde, bunun mRNA'sinin ifade miktarinin
normal intimal hücrelerle karsilastirildiginda önemli ölçüde azaldigi yayinlanmistir
(Bakiniz Patent Belgesi 1).
Ayrica 81 P reseptörlerinin (özellikle S1P2 reseptörleri) portal hipertansiyon ve astimda
bulundugu da belirtilmistir (Bakiniz Patent Olmayan Belge 1). Reseptörlerin fibrosiz ve
kanser baslangici ile iliskili bag doku büyüme faktörlerinin (CTFG'Ier) ifadesine dahil
oldugu da bilinir (Bakiniz Patent Olmayan Belge 2).
Asagidaki bilesikler mevcut bulusun ilgili teknigi olarak bilinir.
S1P2 antagonistik aktivitesine sahip bilesikler olarak, özellikle S1P2 reseptörlerine etki
eden ve fibrosize yönelik terapötik olarak yararli olan genel formül (a):
38 da 5
| jxazvazzawvig (a)
R1? N/ \Rsa
ile temsil edilen pirazopiridin bilesikleri veya onun farmasötik olarak kabul edilebilir
tuzlari, burada R”, R2a ve R:Sa bir C1-8 alkil grubunu temsil eder; R4a bir hidrojen
atomunu temsil eder; R5a ve Rea ayni veya farklidir ve bir hidrojen atomunu, bir 01-8
alkil grubunu, bir C1-6 alkoksi grubunu, bir halojen atomunu temsil eder; X5i -NH-, -O-, -
CH2-'yi temsil eder; Ya -NH-“yi temsil eder; Za -CO-“yu temsil eder; Wa -NH-'yi temsil
eder; ve halka Aa bir aril grubunu, bir heteroaril grubunu temsil eder (ilgili gruplarin
tanimlari özetlenir) açiklanir (Bakiniz Patent Belgesi 2).
S1P2 antagonistik aktivitesine sahip oldugu bilinen bilesikler, genel formül (b):
Ab-X'J-Yb-Zb-Bb (b)
ile temsil edilen bir piperidin iskeletine sahip bilesikleri de içerebilir
burada Ab bir sübstitüent içerebilen siklik bir grubu temsil eder; Xb omurgada 1 ila 3
atoma sahip bir tek bagi veya ara parçayi temsil eder; Yb omurgada 1 ila 3 atoma sahip
bir tek bagi veya ara parçayi temsil eder; Zb omurgada 1 ila 3 atoma sahip bir tek bagi
veya ara parçayi temsil eder; ve Bb bir tek parçayi içerebilen siklik bir grubu (Bakiniz
Patent Belgesi 3) ve bir azetidin iskeletine sahip bilesikleri temsil eder (Bakiniz Patent
Belgesi 4).
Önceki teknik belgeleri, belirli sübstitüsyon pozisyonlarinda iki spesifik sübstitüent,
özellikle bir halojen atomu veya haloalkil grubu ve bir fenoksi grubu içeren bulus
bilesiginin, insan SiPz antagonistik aktivitesini önemli ölçüde gelistirebildigini
açiklamaz veya ileri sürmez.
Patent Belgesi 1: Japon Patent Basvurusu Bülten No. H6-234797
Patent Belgesi 2: WC 01/98301
Patent Disi Belge 1: Biochemical and Biophysical Research Communications, vol. 320,
BULUSUN AÇIKLAMASI
Mevcut bulusun bir amaci, bilesigin çözünürlügünü arttirmak ve tibbi bir ürününü
saglamak üzere Patent Belgesi 3'te açiklanan bilesikler tarafindan yetersiz derecede
gösterilen insan 81 P2 antagonistik aktivitesine sahip bilesikleri saglamaktir.
Mevcut bulusçular, yukaridaki problemi çözmek ve gelismis insan S1P2 antagonistik
aktivitesine sahil bilesigi bulmak amaciyla kapsamli çalismalar yapmistir. Sonuç olarak
mevcut bulusçular, belirli sübstitüsyon pozisyonlarinda spesifik sübstitüentlere, özellikle
bir halojen atomu veya haloalkil grubu ve bir fenoksi grubuna sahip bilesigin, Patent
Belgesi 3'te açiklanan bilesige göre önemli ölçüde gelismis insan S1P2 antagonistik
aktivitesine sahip oldugunu beklenmedik bir sekilde bulmustur, böylelikle mevcut bulus
tamamlanmistir.
Dolayisiyla mevcut bulus, genel formül (I) ile temsil edilen bir bilesige, bir tuzuna,
solvatina veya N-oksidine yönlendirilir:
701/ '~ /
R21 grubu ile sübstitüe edilebilen C2-8 alkenil grubu, (3) 1 ila 5 R21 grubu ile sübstitüe
edilebilen 02-8 alkinil grubu veya (4) C1-4 alkil grubu, Ci-4 haloalkil grubu, Ci-4
alkoksi grubu ve bir halojen atomundan olusan gruptan seçilen 1 ila 5 sübstitüent ile
sübstitüe edilebilen C3-7 karbosikli temsil eder;
R“, (1) halojen atomu, (2) OR22 (bu grupta R”, (1) hidrojen atomu, (2) C1-4 alkil grubu
R24 sirasiyla ve bagimsiz olarak (1) hidrojen atomu veya (2) C1-4 alkil grubunu temsil
eder) veya (4) bir okso grubunu temsil eder;
R2, (1) hidrojen atomu, (2) Ci-4 alkil grubu veya (3) C1-4 haloalkil grubunu temsil eder;
R4, (1) halojen atomu, (2) C1-4 alkil grubu veya (3) C1-4 haloalkil grubunu temsil eder;
L, (1) bir bag, (2) asagidaki formül ile temsil edilen bir grup:
R12 R1::
burada A, (1) bir bag veya (2) bir oksijen atomunu temsil eder; R12 ve R13 sirasiyla ve
bagimsiz olarak (1) hidrojen atomu, (2) Ci-4 alkil grubu, (3) hidroksi grubu veya (4)
NH2'yi temsil eder veya (5) R12 ve R”, eklendikleri karbon atomu ile birlikte 03-?
karbosikl olusturabilir ve sag taraftaki ok, -CONR6R7, -802R8 veya -COOR9'a baglanir,
alkil grubu ile sübstitüe edilebilen bir nitrojen atomunu temsil eder; R6 ve R7 sirasiyla ve
bagimsiz olarak (1) hidrojen atomu, (2) C1-4 alkil grubu, (3) CI-4 haloalkil grubu, (4)
hidroksi grubu, (5) -CONR -SOzR17'yi temsil
eder veya R6 ve R7, eklendikleri nitrojen atomu ile birlikte bir hidroksi grubu ile sübstitüe
edilebilen 4 ila 7 üyeli nitrojen içeren doymus heterosikli olusturabilir; R8, (1) C1-4 alkil
grubu, (2) C1-4 haloalkil grubu veya (3) NR1°R11'i temsil eder;
R9, (1) hidrojen atomu veya (2) C1-8 alkil grubunu temsil eder; R1° ve R11 sirasiyla ve
bagimsiz olarak (1) hidrojen atomu, (2) C -
SOzNR -SOzR17`yi temsil eder;
halka 1, 5 ila 7 üyeli siklik bir grubu temsil eder;
ila 7 üyeli siklik bir grubu temsil eder; R”, (1) C1-4 alkil grubu veya (2) 5 ila 7 üyeli
siklik bir grubu temsil eder;
temsil eder;
M2, bir halojen atomu veya C1-4 haloalkil grubunu temsil eder;
n, 1 ila 2 olan bir tamsayiyi temsil eder;
m, 1 ila 2 olan birtamsayiyi temsil eder;
p, 0 ila 5 olan bir tamsayiyi temsil eder;
r, 0 ila 4 olan bir tamsayiyi temsil eder;
t, 1 ila 4 olan bir tamsayiyi temsil eder;
p, 2 veya daha fazla oldugunda birçok R3 grubu, ayni veya farkli olabilir;
r, 2 veya daha fazla oldugunda birçok R4 grubu, ayni veya farkli olabilir ve
t, 2 veya daha fazla oldugunda birçok R12 ve R13 grubu sirasiyla. ayni veya farkli
olabilir.
Ayni zamanda genel formül (l) ile temsil edilen bilesigi, tuzunu, solvatini veya N-
oksidini içeren farmasötik bir bilesim saglanir.
Bulus ayrica, vasküler daralma, fibrozis, respiratuar hastalik, arteriyoskleroz, periferik
arter tikanikligi hastaligi, retinopati, glokom, yasa bagli maküler dejenerasyon, nefrit,
diyabet, diyabetik komplikasyon, dislipidemi, hepatit, hepatik siroz, hepatik yetmezlik,
nöropati, romatoid artrit, yara, agri, ürtiker, sistemik Iupus eritematozus (SLE) ve
kanserden kaynaklanan bir hastaliktan seçilen 81P2 aracili bir hastaligin profilaksisinde
ve/veya terapisinde kullanilmaya yönelik genel formül (l) ile temsil edilen bilesige, tuzu,
solvati veya N-oksidine veya bunu içeren farmasötik bilesime yönlendirilir.
Mevcut bulusun tercih edilen düzenlemeleri, bagimli istemlerde verilir.
Mevcut bilesik, yüksek insan S1P2 antagonistik aktiviteye sahiptir ve bu nedenle
vasküler daralma ve fibrozisten kaynaklanan hastaliklar gibi S1P2 aracili hastaliklarin
terapisinde faydalidir.
BULUSUN GERÇEKLESTIRILMESINE YÖNELIK EN iYi YÖNTEM
Mevcut bulus, asagida detayli olarak açiklanmaktadir.
Burada kullanilan halojen atomu, flor, klor, brom ve iyot anlamina gelir.
Burada kullanilan C1-8 alkil grubu, örnegin metil, etil, propil, bütil, pentil, hekzil, heptil,
octyl, izopropil, izobütil, sec-bütil, tert-bütil, 1-metilbütil, 1-etilpropil, 1,1-dimetilpropil,
dimetilbütil, 2-metilpentil, 3-metilpentil, 4-metilpentil, 2,3-dimetilbütil, 1-metilhekzil, 1-
etilpentil, 2-etilpentil, 1-propilbütil, 2-metiI-3-hekzil, 1,2-dimetilpentil, 1,3-dimetilpentil,
metilbütil, 1,1-dimetilpentil, 1,1,3-trimetilbütil, 1,1-dietilpropil, 2-metilhekzil, 3-
metilhekzil, 4-metilhekzil, 5-metilhekzil, 3-etilpentil, 1-metilheptil, 2-metilheptil, 3-
1-propilpentil, 2-pr0pilpentil, 1,5-dimetilhekzil, 1-etiI-4-metilpentil, 1-propil-3-metilbütil,
1,1-dimetilhekzil, 1-etiI-1-metilpentil ve 1,1-dietilbütil gruplarini içerebilen lineer veya
dallanmis Cl-8 alkil gruplarini içerebilir.
Burada kullanilan CI-4 alkil grubu, örnegin metil, etil, propil, bütil, izopropil, izobütil, sec-
bütil ve tert-bütil gruplarini içerebilen lineer veya dallanmis C1-4 alkil gruplarini
içerebilir.
Burada kullanilan CI-4 haloalkil grubu, florometil grubu, klorometil grubu, bromometil
grubu, iyodometil grubu, diflorometil grubu, triflorometil grubu, 1-fl0roetil grubu, 2-
floroetil grubu, 2-kl0roetil grubu, pentafloroetil grubu, 1-fl0ropropil grubu, 2-kloropropil
grubu anlamina gelir.
Burada kullanilan C2-8 alkenil grubu, örnegin vinil, propenil, butenil, pentenil, hekzenil,
hekzadienil, heptenil, heptadienil, oktenil, oktadienil, 2-metilpropen-1-il, 2-etil-1-buten-
1-il, 2-metilbuten-2-il ve 2-metilpenten-2-il gruplarini içerebilen lineer veya dallanmis
02-8 alkenil gruplarini içerebilir.
Burada kullanilan C2-4 alkenilen grubu, etenilen, propenilen ve bütenilen gruplarini
içerebilir.
Burada kullanilan 02-8 alkinil grubu, örnegin etinil, propinil, bütinil, pentinil, hekzinil,
hekzadiinil, heptinil, heptadiinil, oktinil, oktadiinil ve 3,3-dimetiI-1-butin-1-il gruplarini
içerebilen lineer veya dallanmis C2-8 alkinil gruplarini içerebilir.
Burada kullanilan C1-4 alkoksi `grubu örnegin, metoksi, etoksi, propoksi, izopropoksi,
butoksi, izobutoksi, sec-butoksi ve tert-butoksi gruplarini içerebilir.
Burada kullanilan C3-7 karbosikl, kismen veya tamamen doymus olabilen ve örnegin
siklopropan, siklobütan, siklopentan, siklohekzan, sikloheptan, siklobuten, siklopenten,
siklohekzan, siklohepten, siklobutadien, siklopentadien, siklohekzadien, sikloheptadien
ve benzen halkalarini içerebilen 03-7 monosiklik karbosikl veya C3-7 karbosikl
anlamina gelir.
Burada kullanilan C5-7 karbosikl, kismen veya tamamen doymus olabilen ve örnegin
siklopentan, siklohekzan, sikloheptan, siklopenten, siklohekzen, siklohepten,
siklopentadien, siklohekzadien, sikloheptadien ve benzen halkalarini içerebilen C5-7
monosiklik karbosikl veya 05-? karbosikl anlamina gelir.
Burada kullanildigi üzere 4 ila 7 üyeli nitrojen Içeren doymus heterosikl, bir oksijen
atomu, nitrojen atomu ve sülfür atomu içeren ve kaçinilmaz olarak bir veya birkaç
nitrojen atomu içeren kismen veya tamamen doymus 4 ila 7 üyeli monosiklik
heterosikllere refere eder. Örnegin azetidin, pirolin, pirolidin, imidazolin, imidazolidin,
triazolin, triazolidin, tetrazolin, tetrazolidin, pirazolin, pirazolidin, dihidropiridin,
tetrahidropiridin, piperidin, dihidropirazin, tetrahidropirazin, piperazin, dihidropirimidin,
tetrahidropirimidin, perhidropirimidin, dihidropiridazin, tetrahidropiridazin,
perhidropiridazin, dihidroazepin, tetrahidroazepin, perhidroazepin, dihidrodiazepin,
tetrahidrodiazepin, perhidrodiazepin, dihidrooksazol, tetrahidrooksazol (oksazolidin),
dihidroizooksazol, tetrahidroizooksazol (izooksazolidin), dihidrotiyazol, tetrahidrotiyazol
(tiyazolidin), dihidroizotiyazol, tetrahidroizotiyazol (izotiyazolidin), dihidrofurazan,
tetrahidrofurazan, dihidrooksadiazol, tetrahidrooksadiazol (oksadiazolidin),
dihidrooksazin, tetrahidrooksazin, dihidrooksadiazin, tetrahidrooksadiazin,
dihidrooksazepin, tetrahidrooksazepin, perhidrooksazepin, dihidrooksadiazepin,
tetrahidrooksadiazepin, perhidrooksadiazepin, dihidrotiyadiazol, tetrahidrotiyadiazol
(tiyadiazolidin), dihidrotiyazin, tetrahidrotiyazin, dihidrotiyadiazin, tetrahidrotiyadiazin,
dihidrotiyazepin, tetrahidrotiyazepin, perhidrotiyazepin, dihidrotiyadiazepin,
tetrahidrotiyadiazepin, perhidrotiyadiazepin, morfolin ve tiyomorfolin halkalarindan
bahsedilebilir.
Burada kullanildigi üzere 5 ila 7 üyeli siklik grup, 05-? karbosikl ve 5 ila 7 üyeli
heterosikl anlamina gelir. 05-?' karbosikl yukaridaki ile ayni anlama sahiptir ve 5 ila 7
üyeli heterosikl, 5 ila 7 üyeli doymamis heterosiklleri ve 5 ila 7 üyeli doymus
heterosiklleri içerebilir. 5 ila 7 üyeli heterosikller örnegin pirolin, pirolidin, imidazolin,
imidazolidin, triazolin, triazolidin, tetrazolin, tetrazolidin. pirazolin, pirazolidin,
dihidropiridin, tetrahidropiridin, piperidin, dihidropirazin, tetrahidropirazin, piperazin,
dihidropirimidin, tetrahidropirimidin, perhidropirimidin, dihidropiridazin,
tetrahidropiridazin, perhidropiridazin, dihidroazepin, tetrahidroazepin, perhidroazepin,
dihidrodiazepin, tetrahidrodiazepin, perhidrodiazepin, dihidrofuran, tetrahidrofuran,
dihidropiran, tetrahidropiran, dihidrooksepin, tetrahidrooksepin, perhidrooksepin,
dihidrotiyofen, tetrahidrotiyofen, dihidrotiyopiran, tetrahidrotiyopiran, dihidrotiyepin,
tetrahidrotiyepin, perhidrotiyepin, dihidrooksazol, tetrahidrooksazol (oksazolidin),
dihidroizooksazole, tetrahidroizooksazol (izooksazolidin), dihidrotiyazol,
tetrahidrotiyazol (tiyazolidin), dihidroizotiyazol, tetrahidroizotiyazol (izotiyazolidin),
dihidrofurazan, tetrahidrofurazan, dihidrooksadiazol, tetrahidrooksadiazol
(oksadiazolidin), dihidrooksazin, tetrahidrooksazin, dihidrooksadiazin,
tetrahidrooksadiazin, dihidrooksazepin, tetrahidrooksazepin, perhidrooksazepin,
dihidrooksadiazepin, tetrahidrooksadiazepin, perhidrooksadiazepin, dihidrotiyadiazol,
tetrahidrotiyadiazol (tiyadiazolidin), dihidrotiyazin, tetrahidrotiyazin, dihidrotiyadiazin,
tetrahidrotiyadiazin, dihidrotiyazepin, tetrahidrotiyazepin, perhidrotiyazepin,
dihidrotiyadiazepin, tetrahidrotiyadiazepin, perhidrotiyadiazepie. morfolin, tiyomorfolin,
oksatiyan, dioksolan, dioksan, ditiyolan, ditiyan, pirol, imidazol, triazoli tetrazol, pirazol,
piridin, pirazin, pirimidin, piridazin, azepin, diazepin, furan, piran, oksepin, tiyofen,
tiyopiran, tiyepin, oksazol, izooksazol, tiyazol, izotiyazol, furazan, oksadiazol, oksazin,
oksadiazin, oksazepin, oksadiazepin, tiyadiazol, tiyazin, tiyadiazin, tiyazepin ve
tiyadiazepin halkalarini içerebilir.
Mevcut bulusta R1 tercihen, 1 ila 5 R21 grubu ile sübstitüe edilebilen C1-8 alkil grubu
veya Ci -4 alkil grubu, C1-4 haloalkil grubu, CI-4 alkoksi grubu ve halojen atomundan
olusan gruptan seçilen 1 ila 5 sübstitüent ile sübstitüe edilebilen 05-?' karbosikl ve daha
çok tercih edildigi üzere dallanmis C1-8 alkil grubu veya halojen atomu ve triflorometil
grubu ile sübstitüe edilebilen bir siklopentan, siklohekzan veya benzen halkasidir.
Dallanmis 01-8 alkil grubu tercihen, bir izopropil, izobütili 2-etilbütil, 2-metilpentil veya
3-metilpentil grubudur.
Mevcut bulusta R21 tercihen, bir flor atomudur.
Mevcut bulusta R2 tercihen, bir hidrojen atomudur.
Mevcut bulusta R3 tercihen, -L-CONR6R7, -L-SOzR8 veya -L-COORg'dur.
Mevcut bulusta M1 tercihen, -0- veya -C(O)O-'dur.
Mevcut bulusta M2 tercihen, bir flor atomu, klor atomu veya CI-4 haloalkil grubu, daha
çok tercih edildigi üzere C1-4 haloalkil grubudur ve CI-4 haloalkil grubu tercihen,
florometil grubu, diflorometil grubu veya triflorometil grubudur.
Mevcut bulusta halka 1 tercihen bir benzeri, piridazin, pirimidin, pirazin, piridin veya
siklohekzan halkasi ve daha çok tercih edildigi üzere bir benzen halkasidir.
Mevcut bulusta genel formül (I) ile temsil edilen bilesik tercihen, genel formül (H) ile
temsil edilen bir bilesiktir:
(R3),
burada tüm semboller, yukaridaki ile ayni anlama sahiptir. Genel formülde (I-1) R2
tercihen bir hidrojen atomudur; R3 tercihen, -L-CONR5R7, -L-802R8 veya -L-COOR9 ve
daha çok tercih edildigi üzere -L-CONR5R70r -L-COOR9`dur; M2 tercihen florometil
grubu, diflorometil grubu veya triflorometil grubudur ve daha çok tercih edildigi üzere
triflorometil grubudur; halka 1 tercihen benzen, piridin veya siklohekzan halkasidir ve
halka 1 daha çok tercih edildigi üzere bir benzen halkasidir.
Mevcut bulusta genel formül (I) ile temsil edilen bilesik tercihen, genel formül (H) ile
temsil edilen bir bilesiktir:
R1-1x/c/vm ?2
(R4), 11/ 1/
(R3),
burada tüm semboller, yukaridaki ile ayni anlama sahiptir. Genel formülde (I-1) R2
tercihen, bir hidrojen atomudur; R3 tercihen, -L-CONR6R7, -L-SOzR8 veya -L-COOR9 ve
daha çok tercih edildigi üzere -L-CONRGR7 veya -L-COOR9'dur; M2 tercihen, Cl-4
haloalkil grubudur; C1-4 haloalkil grubu daha çok tercih edildigi üzere bir florometil
grubu, diflorometil grubu veya triflorometil grubudur; halka 1 tercihen, benzen, piridin
veya siklohekzan halkasidir ve daha çok tercih edildigi üzere bir benzen halkasidir.
Mevcut bulusta Örneklerde açiklanan bilesikler daha çok tercih edilir ve özellikle 4-
siklopentiI-4-hidroksi-N-[3-{4-[(metilsülfoniI)karbamoiI]ph enoksi}-5-(trifl0rometiI)feniI]-1-
piperidin karboksamid veya 1-{4-[3-{[(3-siklohekziI-3-hidroksi-1-pirolidinil)karb0nil]amin
o}-5-(triflorometiI)fenoksi]fenil}siklopentankarboksilik asit tercih edilir.
Mevcut bulus, aksi özellikle belirtilmedikçe tüm izomerleri kapsar. Örnegin alkil grubu,
lineer ve dallanmis gruplari içerir. Ayrica mevcut bulus, çift baglar, halkalar ve
yogusmus halkalara yönelik geometrik izomerler (E-formlari, Z-formlari, cis formlari ve
trans formlari) asimetrik karbon atomlarindan kaynaklanan optik izomerler (R ve S
formlari, oi ve B konfigürasyonlari, enantiyomerler ve diastereomerler), optik rotasyon
aktivitesine sahip optik olarak aktif maddeler (D, L, d ve I formlari), kromatografi ile
ayrilabilen polar maddeler (yüksek polariteli maddeler ve düsük polariteli maddeler),
denge bilesikleri, rotamerler, rastgele oranlardaki karisimlari ve rasemik karisimlari
Mevcut bulusa göre optik izomerler, sadece %100 safliga sahip olanlari degil ayni
zamanda diger optik izomerleri %50'den az içerenleri içerebilir.
Mevcut bulusta aksi özellikle belirtilmedikçe asagidaki sembol:
bagin, kagit düzleminden asagi çikinti yaptigini (yani o konfigürasyon) gösterir,
asagidaki sembol:
Bagin, kagit düzleminin üzerine çikinti yaptigini (yani [3 konfigürasyon) gösterir ve
asagidaki sembol:
bagin, teknikte uzman bir kisi için anlasilir oldugu üzere 0( konfigürasyon, ß
konfigürasyon veya bu konfigürasyonlarin rastgele oranlardaki karisimi oldugunu
gösterir.
Genel formül (I) ile temsil edilen bilesik iyi bilinen bir yöntemle tuza dönüstürülür. Tuz
tercihen suda çözülebilirdir. Uygun tuzlar alkali metal (örnegin potasyum veya sodyum)
tuzlari, toprak alkali metal (örnegin kalsiyum veya magnezyum) tuzlari, amonyum
tuzlari, farmasötik olarak kabul edilebilir organik amin (örnegin tetrametilamonyum,
trietilamin, metilamin, dimetilamin, siklopentilamin, benzilamin, fenetilamin, piperidin,
monoetanolamin, dietanolamin, tris(hidroksimetil)amin0metan, Iisin, arginin veya N-
metiI-D-glukamin) tuzlar veya asit katki tuzlari (inorganik asit tuzlari (örnegin
hidrokloridler, hidrobromidler, hidroiyodidler, sülfatlar, fosfatlar veya nitratlar), organik
asit tuzlarini (örnegin asetatlar, trifloroasetatlar, Iaktatlar, tartaratlar, oksalatlar,
fumaratlar, maleatlar, benzoatlar, sitratlar, metan sülfonatlar, etan sülfonatlar, benzen
sülfonatlar, tolüen sülfonatlar, Izetionatlar, glukuronatlar veya glukonatlar) içerebilir.
Genel formül (I) ile temsil edilen bilesik ve bunun tuzu bir solvata da dönüstürülebilir.
Solvat tercihen düsük toksisiteye sahiptir ve suda çözünebilir. Uygun solvatlar, örnegin
su ve alkollü solventler (örnegin etanol) içerebilir.
Genel formül (I) ile temsil edilen bilesigin N-oksidi. yukarida açiklandigi üzere nitrojen
atomunun okside edildigi genel formül (I) ile temsil edilen bilesige refere eder. Genel
formül (I) ile temsil edilen bilesigin N-oksidi ayni zamanda, alkali (toprak alkali) metal
tuzu, amonyum tuzu, organik amin tuzu ve ilave asit tuzu olabilir. Genel formül (I) ile
temsil edilen bilesik, bir izotop (örnegin
Mevcut bilesik, iyi bilinen yöntemler, örnegin Comprehensive Organic Transformations:
A Guide to Functional Group Preparations, 2nd Edition'da (Richard C. Larook, John
Wiley & Sons Inc, 1999) açiklanan yöntem veya uygun modifikasyonlar ve
kombinasyonlar ile Örneklerde açiklanan yöntem ile üretilebilir.
R2'nin bir hidrojen atomu ve M1'in bir oksijen atomu oldugu genel formülün (I) bilesigi,
diger bir deyisle genel formül (I-A) ile temsil edilen bilesik, reaksiyon semasi 1 ile
asagidaki sekilde üretilebilir:
(R3),
burada tüm semboller, yukaridaki ile ayni anlama dahiptir:
Reakslyon Semasi 1
0 N. . MI (Rita J
2 `î"\/ "n /
(A) halim mn
NO; \ ;"033), k.)`\(RI)p
H HQ pat/"51)" a M3
T"N^\ 'M2 tipki** (nm: Y Y /
i %1?" o 1 ,
7._xî \. .; (R4), V'
Reakno* 3 haim' ReaGiyon :1 ("A)
1 ) “ßu“, mi,,
burada T, karbonil grubuna (örnegin 2,2,2-trikl0roet0ksikarb0nil (Troc) grubu,
fenoksikarbonil grubu ve p-nitrofenoksikarbonil grubu) sahip amino grubunun koruma
grubunu temsil eder; X1, bir halojen atomunu temsil eder ve diger semboller, yukaridaki
ile ayni anlama sahiptir.
Reaksiyon adim formülünde (1), reaksiyon (1), genel formül (A) ile temsil edilen bilesik
ve genel formül (ll) ile temsil edilen bilesik arasinda bir eterifikasyon reaksiyonu olarak
gerçeklestirilebilir. Bu eterifikasyon reaksiyonu iyi bilinir ve örnegin bir alkali metal
hidroksidin (sodyum hidroksid, potasyum hidroksid, Iityum hidroksid), bir alkali metal
hidridin (sodyum hidrid), bir toprak alkali metal hidroksidin (baryum hidroksid, kalsiyum
hidroksid), bir fosfat (bir potasyum fosfat) veya bir karbonat (sezyum karbonat, sodyum
karbonat, potasyum karbonat) veya bunun bir sulu çözeltisinin veya bunun bir
karisiminin varliginda, bir organik solventte (N,N-dimetilasetamid, N,N-
dimetilformamid, dimetil sülfoksit, kloroform, diklorometan, dietil eter, tetrahidrofuran,
metil t-bütil eter) ve 0 ila 100°C sicaklikta geçeklestirilir.
Reaksiyon adim formülünde (1), reaksiyon (2), genel formül (B) ile temsil edilen
bilesigin nitro grubunun indirgeme reaksiyonu olarak gerçeklestirilebilir. Genel formül
(B) ile temsil edilen bilesigin nitro grubunun indirgenme reaksiyonu iyi bilinir ve örnegin
asagida açiklanan yöntemlerle gerçeklestirilir.
(1) Reaksiyon, örnegin, bir hidrojenasyon katalistinin (paladyum-karbon,
paladyum karasi, paladium, paladyum hidroksid, platinyum dioksid, platinyum-
karbon, nikel, Raney nikeli, rutenyum klorid) varliginda, bir asitin (hidrokllorik
asit, sülfürük asit, hipoklorüs asit, borik asit, oksalik asit, tetrafloroborik asit,
asetik asit, p-toluen sülfonik asit, oksalik asit, trifloroasetik asit, formik asit)
varliginda veya yoklugunda, bir solventte [eterler (tetrahidrofuran, dioksan,
dimetoksetan, dietil eter), alkoller (metanol, etanol), benzenler (benzen, tolüen),
ketonlar (aseton, metil etiyl keton), nitriller (asetonitril), amidler
(dimetilformamid), su, etil asetat, asetik asit veya yukaridakilerden iki veya daha
fazlasini içeren karisik solventler], normal veya artirilmis basinçli bir hidrojen
atmosferinde, amonyum formatin veya hidrazinin varliginda ve 0 ila 200°C
sicaklikta gerçeklestirilir.
(2) Reaksiyon, örnegin, bir asitin (hidroklorik asit, hidrobromik asit, amonyum
klorid, asetik asit, amonyum format) varliginda veya yoklugunda, bir su ile
karisan bir solventte (etanol, metanol, tetrahidrofuran ve benzeri), 0 ila 150°C
sicaklikta bir metal reaktifi (örnegin çinko demir, kalay, kalay klorür, demir
klorür, samaryum, indiyum veya sodyum borohidrid-nikel klorür) kullanarak
gerçeklesti rilir.
Reaksiyon adim formülünde (1), reaksiyon (3) iyi bilinir ve genel formül (C) ile temsil
edilen bilesik ve genel formül (IlI) ile temsil edilen bilesik ile, örnegin, bir bazin (piridin,
trietilamin, dimetilanilim, dimetilaminopiridin, diizopropiletilamin) varliginda genel formül
(III) ile temsil edilen bilesigin genel formül (C) ile temsil edilen bilesik ile bir organik
solventte (kloroform, diklorometan, dietil eter, tetrahidrofuran) 0 ila 40°C arasindaki oda
sicakliginda reaksiyonuyla gerçeklestirilir. Genel formül (III) ile temsil edilen bilesik, bir
organik solventte (etil asetat, dioksan, tetrahidrofuran), bir alkali sulu solüsyon (sodyum
hidrojen karbonat solüsyonu, sodyum hidroksid solüsyonu) kullanarak 0 ila 40°C
sicaklikta formül (C) ile reaksiyona tabi tutulabilir.
Reaksiyon adim formülünde (1), reaksiyon (4) iyi bilinir ve genel formül (D) ile temsil
edilen bilesik ve genel formül (IV) ile temsil edilen bilesik ile, örnegin bir bazin (piridin,
trietilamin, dimetilanilim, dimetilaminopiridin, diizopropiletilamin) varliginda, genel
formül (D) ile temsil edilen bilesik ile genel formül (IV) ile temsil edilen bilesigin, bir
organik solventte (N,N-dimetilasetamid, kloroform, dikllorometan, dietil ether,
tetrahidrofuran) 0°C ila reflüks sicakliginda reaksiyonuyla gerçeklestirilir.
Reaksiyon adim formülünde (1), formül ile temsil edilen bilesik koruma grubuna sahip
oldugunda, örnegin, R3 korundugunda, gerekirse korumasiz birakma reaksiyonu
gerçeklestirilebilir. Koruma gruplarinin korumasiz birakma reaksiyonu iyi bilinir ve
örnegin, (1) alkali hidroliz ile korumasiz birakma reaksiyonu, (2) asitik kosullar altinda
korumasiz birakma reaksiyonu, (3) hidroliz ile korumasiz birakma reaksiyonu, (4) silil
gruplarin korumasiz birakma reaksiyonu, (5) bir metal kullanan korumasiz birakma
reaksiyonu, (6) bir metal kompleksi kullanan korumasiz birakma reaksiyonu içerebilen
asagidaki yöntemlerle gerçeklestirilebilir.
Bu yöntemler özellikle asagida açiklanmistir.
(1) Alkalin hidrolizi ile korumasiz birakma reaksiyonu, örnegin, bir organik
solventte (örnegin metanol, tetrahidrofuran ve dioksan), 0 ila 40°C sicaklikta bir
alkali metal hidroksid (örnegin sodyum hidroksid, potasyum hidroksid and Iityum
hidroksid), bir toprak alkali metal hidroksid (örnegin baryum hidroksid ve
kalsiyum hidroksid) veya bir karbonat (örnegin sodyum karbonat ve potasyum
karbonat) veya bunun bir sulu solüsyonu veya bunun bir karisimini kullanarak
gerçeklestirilir.
(2) Asitik kosullar altinda korumasiz birakma reaksiyonu, örnegin bir organik
solventte (örnegin diklorometan, kloroform, dioksan, etil asetat, metanol,
izopropil alkol, tetrahidrofuran ve anisol) ve bir organik asitte (örnegin asetik
asit, trifloroasetik asit, metanesulfonik asit ve p-tosilik asit) veya bir inorganik
asitte (örnegin hidroklorik asit ve sülfürik asit) veya bunun bir karisiminda
(örnegin hidrojen bromId/asetik asit) 2,2,2-triflor0etanol varliginda veya
yoklugunda 0 ila 100°C sicaklikta gerçeklestirilir.
(3) Hidroliz ile korumasiz birakma reaksiyonu, örnegin, bir solventte (örnegin
eterler (örnegin tetrahidrofuran, dioksan, dimetoksetan ve dietil eter), alkoller
(örnegin metanol ve etanol), benzenler (örnegin benzeri ve toluen), ketonlar
(örnegin aseton ve metil etil keton), nitriller (örnegin benzen ve toluen), amidler
(örnegin N,N-dimetilf0rmamid), su, etil asetat, asetik asit veya yukaridakilerden
iki veya daha fazlasinin karisik solventleri), bir katalistin (paladyum-karbon,
paladyum karasi, paladyum hidroksid-karbon, platin oksit ve Raney nikeli),
normal veya artirilmis basinçli bir hidrojen atomosferinde veya amonyum
formatin varliginda 0 ila 200°C sicaklikta gerçeklestirilir.
(4) Silil gruplari korumasiz birakma reaksiyonu, örnegin su ile karisabilen bir
organik solventte (örnegin tetrahidrofuran ve asetonitril), tetrabutilamonyum
florid kullanarak 0 ila 40°C sicaklikta gerçeklestirilir. Alternatif olarak, reaksiyon,
örnegin bir organik asitte (örnegin asetik asit, trifloroasetik asit, metansulfonik
asit ve p-tosilik asit) veya bir inorganik asitte (örnegin hidroklorik asit ve sülfürik
asitte) veya bunun bir karisiminda (örnegin hidrojen bromid/asetik asit) -10 ila
100°C sicaklikta gerçeklestirilir.
(5) Bir metal kullanarak korumasiz birakma reaksiyonu, örnegin bir asitik
solventte (örnegin asetik asit, 4.2 ila 7.2 pH degerine sahip tampon veya bunun
tetrahidrofuran gibi bir organik solvent ile karisimi) çinko tozu varliginda
ultrasonik uygulamayla, gerekirse, 0 ila 40°C sicaklikta gerçeklestirilir.
(6) Bir metal kullanarak korumasiz birakma reaksiyonu örnegin, bir yakalama
reaktifinin (örnegin tribütiltin hidrid, trietilsilan, dimedon, morfolin, dietilamin ve
pirolidin) varliginda, bir organik asitin (örnegin asetik asit, formik asit ve 2-
etileksanoik asit) ve/veya bir organik asit tuzunun (örnegin sodyum 2-
etileksanoat ve potasyum 2-etileksan0at) varliginda, bir fosfin reaktifinin
(örnegin trifenilfosfin) varliginda veya yoklugunda, bir organik solventte (örnegin
diklorometan, N,N-dimetilformamid, tetrahidrofuran, etil asetat, asetonitril,
dioksan ve etanol), su veya bunun karisik bir solventinde bir metal kompleks
(örnegin tetrakis trifenilfosfin paladyum (O), bis(trifenilfosfin)paladyum (II)
diklorid, paladyum (II) asetat ve tris(trifenilfosfin)rodyum (l) klorid) kullanarak 0
ila 40°C sicaklikta gerçeklestirilir.
Alternatif olarak, korumasiz birakma reaksiyonu örnegin, T. W. Greene, Protective
Groups in Organic Synthesis, Wiley, New York, 1999`da açiklanan yöntemle
gerçeklestirilebilir.
Hidroksi grubunun koruma grubu örnegin, bir metil grubu, bir tritil grubu. bir
metoksimetil (MOM) grubu, bir 1-etoksietil (EE) grubu, bir metoksietoksimetil (MEM)
grubu, bir 2-tetrahidr0piranil (THP) grubu, trimetilsilil (TMS) grubu, trietilsilil (TES)
grubu, bir t-butildimetilsilil (TBDMS) grubu, bir t-butildifenilsilil (TBDPS) grubu, bir asetil
(Ac) grubu, bir pivaloil grubu, bir benzoil grubu, bir benzil (Bn) grubu, bir p-
metoksibenzil grubu, bir aliloksikarbonil (Alloc) grubu ve bir 2,2,2-triklor0etoksikarbonil
(Troc) grubu içerebilir.
Bir amino grubun koruma grubu örnegin, bir benziloksikarbonil grubu, bir t-
butoksikarbonil grubu, bir aliloksikarbonil (Alloc) grubu, bir 1-metiI-1-(4-
bifenil)etoksikarbonil (Bpoc) grubu, bir trifluoroasetil grubu, bir 9-fl0renilmetoksikarbonil
grubu, bir benzil (Bn) grubu, bir p-metoksibenzil grubu, bir benziloksimetil (BOM) grubu,
ve 2-(trimetilsill)etoksimetil (SEM) grubu içerebilir.
Bir hidroksi grubun koruma grubu kolaylikla ve selektif olarak ortadan kaldirilabildigi
için özellikle yukarida belirtilenlerle sinirli degildir. Örnegin, T. W. Greene, Protective
Groups in Organic Synthesis, Wiley, New York, 1999'da çiklananlar kullanilabilir.
Burada açiklanan reaksiyonlarda, genel formül (A), (II), (III) ve (IV) ile temsil edilen
bilesikler gibi baslangiç materyalleri olarak kullanilan bilesikler iyi bilinir veya iyi bilinen
yöntemlere göre kolaylikla üretilebilir.
Burada açiklanan reaksiyonlarda, isitmaya eslik eden reaksiyonlar teknikte uzman bir
kisiye göre, bir su banyosu, bir yag banyosu, bir kum banyosu veya bir mikro dalga ile
gerçeklesti rilebilir.
Burada açiklanan reaksiyonlarda, bir yüksek moleküler polimerde (örnegin polistiren,
poliakrilamid, polipropilen ve polietilen glikol) immobilize olan bir kati faz immobilize
reaktifi kullanilabilir.
Burada açiklanan reaksiyonlarda, reaksiyon ürünleri normal veya azaltilmis basinçta
distilasyon, yüksek performansli sivi kromatografisi gibi klasik pürifikasyon araçlarina
göre silika jel veya magnezyum silikat, ince katman kromatografisi, iyon degisimi
reçineleri, tutucu reçineler veya kolon kromatografisi veya yikama ve yeniden
kristalizasyon kullanarak saflastirilabilir. Pürifikasyon her reaksiyondan ve birkaç
reaksiyon sonra gerçeklestirilebilir.
Mevcut bilesik yeterince düsük toksisiteye sahiptir ve bu yüzden güvenle bir ilaç olarak
kullanilabilir.
Mevcut bulus bilesigi, S antagonistik aktiviteye sahiptir ve bu nedenle
S1P2-aracili bir hastaliga yönelik profilaktik ve/veya terapötik ajan olarak faydalidir.
S1P2-aracili hastalik, vasküler daralma, fibrozis, respiratuar hastalik, arteriyoskleroz,
periferik arter tikanikligi hastaligi, retinopati, glokom, yasa bagli maküler dejenerasyon,
nefrit, diyabet, diyabetik komplikasyon (diyabetik retinopati ve diyabetik nefropati de
dahil), dislipidemi, hepatit, hepatik siroz, hepatik yetmezlik (alkolik olmayan
steatohepatit, alkolik steatohepatit ve viral hepatit de dahil), nöropati, romatoid artrit,
yara, agri, ürtiker, sistemik Iupus eritematozus (SLE) ve kanseri içerir.
Mevcut bulusta vasküler daralmadan kaynaklanan hastalik, serebral vazospastik
hastalik, kardiyak vazospastik hastalik, koroner vazospastik hastalik, hipertansiyon,
pulmoner hipertansiyon, miyokard enfarktüsü, anjina, aritmi, atriyel fibrilasyon, portal
hipertansiyon, varis, assit, splenomegali, hepatik ensefalopati, iskemi-reperfüzyon
hasarini içerebilir.
Burada kullanildigi üzere fibrozis, pulmoner fibrozis, hepatik fibrozis, böbrek fibrozisi,
miyokard fibrozisi, Cilt fibrozisini içerebilir.
Burada kullanilan respiratuar hastalik, bronsiyal astim, akut akciger yaralanmasi,
sepsis, kronik obstrüktif akciger hastaligini içerebilir.
Mevcut bulusta varis, özofageal varis, mide varisi, duodenal varis, enterik varis, kolonik
varis, rektal varisi içerebilir.
Mevcut bilesik, portal basinci düsürebilir ve bu nedenle, portal hipertansiyona yönelik
profilaktik ve/veya terapötik ajan olarak ve portal hipertansiyon ile iliskili özofageal
varisten kaynaklanan primer veya sekonder kanamaya yönelik profilaktik bir ajan olarak
kullanilabilir.
Mevcut bilesik, portal basinci kalici olarak düsürebilir ve bu nedenle günde bir kez
uygulama ile portal hipertansiyonun profilaktik ve/veya terapötik etkisini gösterebilir.
Mevcut bilesik asagidakileri yapmak amaciyla bir konkomitan ilaç olarak uygulanacak
sekilde baska bir ilaç ile birlestirilebilir:
1) mevcut bilesigin profilaktik ve/veya terapötik etkisini tamamlama ve/veya
gelistirme;
2) mevcut bilesigin kinetigini ve alimini iyilestirme ve dozajini azaltma; ve/veya
3) mevcut bilesigin yan etkisini artirma.
Mevcut bilesigin konkomitan ilaci ve baska bir ilaç her iki bileseni bir formülasyonda
içeren kombine bir ajan olarak veya ayri ayri uygulanabilir. Bu ayri uygulama
eszamanli uygulamayi ve sirali uygulamayi içerebilir. Sirali uygulama baska bir ilaçtan
önce mevcut bilesigin uygulanmasini ve mevcut bilesikten önce baska bir ilacin
uygulanmasini içerebilir. Bilesenlerin uygulanma sekilleri ayni veya farkli olabilir.
Konkomitan ilaç, mevcut ilacin profilaktik ve/veya terapötik etkisi tamamlandigi ve/veya
gelistirildigi sürece sinirlama olmadan her hastalik için profilaktik ve/veya terapötik etki
gösterebilir.
Vasküler daralmadan kaynaklanan mevcut bilesigin profilaktik ve/veya terapötik etkisini
tamamlama ve/veya gelistirmeye yönelik kullanilan baska bir ilaç, örnegin kalsiyum
antagonistleri, trombolitik ajanlar, tromboksan sentaz inhibitörleri, endotelin
antagonistleri, antioksidanlar, radikal tutucular, PARP inhibitörleri, astrosit islevini
iyilestirme ajanlari, Rho kinaz inhibitörleri, anjiyotensin lI antagonistler, anjiyotensin-
dönüstürme enzim inhibitörleri, enzim inhibitörleri, diüretik ajanlar, fosfodiesteraz (PDE)
4 inhibitörleri, prostaglandinler (bundan böyle PG veya PG'Ier olarak kisaltilir),
aldosteron antagonistler, endotelin antagonistler, prostasilin formülasyonlari, nitratlari,
ß-bloke edicileri, vazodilatörleri içerebilir.
Fibrosize yönelik mevcut bilesigin profilaktik ve/veya terapötik etkisinin tamamlanmasi
ve/veya gelistirilmesi için kullanilan baska bir ilaç, örnegin steroidleri,
immünosüpresanlar, TGF-ß inhibitörleri, PDE5 inhibitörleri ve benzerlerini içerebilir.
Solunum hastaligina yönelik mevcut bilesigin profilaktik ve/veya terapötik etkisinin
tamamlanmasi ve/veya gelistirilmesi için kullanilan baska bir ilaç, örnegin, PDE4
inhibitörleri, steroidleri, ß-agonistleri, Iökotrien alici antagonistleri, trombolsan sentaz
inhibitörleri, tromboksan A2 reseptör antagonistleri, araci salim baskilama ajanlari,
antihistaminleri, ksanthin türevleri, antikolinerjik ajanlar, sitokin inhibitörleri, PG'Ieri,
forskolin formülasyonlari, elastaz inhibitörleri, metaloprotaz inhibitörleri,
ekspektoranlari, antibiyotikleri içerebilir.
Kalsiyum antagonistleri örnegin, nifedipin, benidipin hidrokloridi, diltiazem hidrokloridi,
verapamil hidrokloridi, nisoldipini, nitrendipini, bepridil hidrokloridi, amlodipin besilati,
alteplazi, ürokinazi, tisokinazi, nasaruplazi, nateplazi, doku plasminojen aktivatörü,
pamiteplazi, monteplazi içerebilir. Tromboksan sentaz inhibitörleri örnegin, ozagrel
hidrokloridi, imitrodast sodyumu içerebilir. Radikal tutucular, örnegin Radicut'u
içerebilir. PARP inhibitörleri örnegin, 3-amin0benzamid, 1,3,7-trimetilksantini, PD-
Astrosit fonksiyonu iyilestirme ajanlari örnegin, ONO-2506'yi içerebilir.
Rho kinaz inhibitörleri örnegin fasudil hidrokloridi içerebilir.
Anjiotensin II antagonistleri örnegin, Iosartan, kandesartan, valsartan, irbesartan,
olmesartan, telmisartani içerebilir.
Anjiyotensin dönüstürme enzimi inhibitörleri örnegin, Iasepril, imidapril hidrokloridi,
kinapril hidrokloridi, temokapril hirokloridi, delapril hidrokloridi, benazepril hidrokloridi,
kaptopril, trandolapril, perindopril erbümin, enalapril maleat, Iisinoprili içerebilir.
Diüretik ajanlar örnegin, mannitol, furosemid, asetazolamid, diklorofenamid,
triklormetiazi, mefrusid, spironolakton, aminofilini içerebilir.
4396, lC-485'I içerebilir.
Prostaglandinler (PG'ler) örnegin, PG reseptör agonistleri, PG reseptör antagonistlerini
içerebilir.
PG reseptör örnegin, PGE reseptörleri (EP1, EP2, EP3 ve EP4), PGD reseptörleri (DP
ve CRTH2), bir PGF reseptörü (FP), bir PGI reseptörü (IP), bir tromboksan reseptörünü
(TP) içerebilir.
Aldosteron antagonistleri örnegin, drospirenon, metirapon, kanrenoat potasyum,
kanrenon, eplerenon, ZK-91587'yi içerebilir.
Prostasilin formülasyonlari örnegin, treprostinil sodyum, epoprostenol sodyum,
beraprost sodyumu içerebilir.
Nitratlar örnegin, amil nitrit, nitrogliserin, izosorbid dinitrati içerebilir.
ß-bloke ediciler örnegin, alprenolol hidroklorid, bupranolol hidroklorid, bufetolol
hidroklorid, oksiprenolol hidroklorid, atenolol, bisoprolol fumarat, betaksolol hidroklorid,
bevantolol hidroklorid, metoprolol tartarat, asebutolol hidroklorid, seliprolol hidroklorid,
nipradilol, tilisolol hidroklorid, nadorol, propranolol hidroklorid, indenolol hidroklorid,
karteolol hidroklorid, pindolol, bunitrolol hidroklorid, Iandiolol hidroklorid, esmolol
hidroklorid, arotinolol hidroklorid, karvedilol, timolol maleati içerebilir.
Vazodilatörler örnegin, diltiazem hidroklorid, trimetazidin hidroklorid, dipiridamol,
etanofen hidroklorid, dilazep hidroklorid, trapidil, nikorandili içerebilir.
Steroidler oral uygulama veya enjeksiyona yönelik ajanlar olarak örnegin kortizon
asetat, hidrokortizon, hidrokortizon sodyum fosfat, hidrokortizon sodyum süksinat,
fludrokortizon asetat, prednisolon, prednisolon asetat, prednisolon sodyum süksinat,
prednisolon bütilasetat, prednisolon sodyum fosfat, halopredon asetat,
metilprednisolon, metilprednisolon asetat, metilprednisolon sodyum süksinat,
triamsinolon, triamsinolon diasetat, triamsinolon asetonid, deksametason,
deksametason asetat, deksamethason sodyum fosfat, deksametason palmitat,
parametason asetat, betametasonu içerebilir. Inhalasyon steroidleri örnegin,
beklometason propionat, flutisason propionati. budesonid, flunisolid, triamsinolon. ST-
126P, siklesonid, deksametason palomitionat, mometason furonat, prasteron sulfonat,
deflazakort, metilprednisolon sleptanat, metilprednisolon sodyum süksinati içerebilir.
Immünosüpresanlar örnegin, azatioprin, mizoribin, metotreksat, miyosofenolat mofetil,
siklofosfamid, siklosporin A, takrolimus, sirolimus, everolimus, prednisolon,
metilprednisolon, ortoklon OKT3, anti-human Iimfosit globülin, deokspergualin içerebilir.
PDE5 inhibitörleri örnegin sildenafil, tadalafil, vardenafil, udenafili içerebilir.
B agonistleri örnegin, fenoterol hidrobromid, salbutamol sulfat, terbutalin sulfat,
formoterol fumarat, salmeterol ksinafoat, izoproterenol sülfat, orciprenalin sülfat,
klorprenalin sülfat, epinefrin, trimetokinol hidroklorid, heksoprenalin sülfat, prokaterol
hidroklorid, tulobuterol hidroklorid, tulobuterol, pirbuterol hidroklorid, klenbuterol
hidroklorid, mabuterol hidroklorid, ritodrin hidroklorid, bambuterol, dopeksamin
Leukotrien reseptörü antagonistleri örnegin, pranlukast hidrati, montelukast, zafirlukast,
seratrodasti içerebilir.
Tromboksan A2 reseptörü antagonistleri örnegin, seratrodast, ramatroban, domitroban
kalsiyum hidrati içerebilir.
Araci salimini baskilama ajanlari örnegin, tranilast, kromolin sodyum, amileksanoks,
repirinast, ibudilast, tazanolast, pemirolast potasyumu içerebilir.
Antihistaminler örnegin, ketotifen fumarat, mekitazin, azelastin hidroklorid, oksatomid,
terfenadin, emedastin fumarat, epinastin hidroklorid, astemizol, ebastin, setirizin
hidroklorid, bepotastin, feksofenadin, Ioratadin, desloratadin, olopatadin hidroklorid,
oranofin, akrivastini içerebilir.
Ksantin türevleri örnegin, aminofilin, teofilin, doksofilin, sipamfilin, diprofilini içerebilir.
Antikolinerjik ajanlar örnegin ipratropyum bromidi, oksitropyum bromidi, flutropyum
bromidi, simetropyum bromidi, temiverin, tiotropyum bromidi, revatropati içerebilir.
Siyotokin inhibitörleri örnegin suplatast tosilati içerebilir.
665'l içerebilir.
Ekspektoranlar örnegin, foeniküle amonyak ruhunu, sodyum hidrojen karbonat,
bromheksin hidroklorid, karbosistein, ambroksol hidroklorid, ambroksol hidroklorid
sürekli salim preparasyonu, metilsistein hidroklorid, asetilsistein, L-etilsistein
hidroklorid, tiloksapol içerebilir.
Antibiotikler örnegin, sefuroksim sodyum, meropenem trihidrat, netilmisin sülfat,
astromisin sülfat, sefetamet pivoksil hidroklorid. Inhalasyon antibiotikleri örnegin, PA-
hidroklorid içerebilir.
Mevcut bilesik genellikle oral veya parenteral formda sistematik veya yerel olarak
uygulanir. Oral formülasyonlari örnegin, oral uygulamaya yönelik sivilar (örnegin
eliksirler, suruplar, farmasötik olarak kabul edilebilir solüsyonlar, süspansiyonlar ve
emülsiyonlar), oral uygulamaya yönelik kati maddeler (örnegin tabletler (dil alti tabletler
ve agizda çözünen tabletler), haplar, kapsülleri (sert kapsüller, yumusak kapsüller,
jelatin kapsüller ve mikrokapsüller), tozlar, granüller ve troseler) içerebilir. Parenteral
formülasyonlar örnegin sivilari (örnegin enjeksiyonlari (deri alti enjeksiyonlari, damar
için enjeksiyonlari, kas içi enjeksiyonlari, karin içi enjeksiyonlari, infüzyonlar), oftalmik
solüsyonlar (örnegin sulu oftalmik solüsyonlari (sulu oftalmik solüsyonlari, sulu oftalmik
solüsyonlar, viskoz oftalmik solüsyonlar ve çözülebilir oftalmik solüsyonlar), susuz
oftalmik solüsyonlar (susuz oftalmik solüsyonlar, susuz oftalmik süspansiyonlar),
topikal formülasyonlari (örnegin merhemler (oftalmik merhemler)), kulak damlalarini
içerebilir. Bu formülasyonlar hizli salim preparasyonlari veya sürekli salim salimlari gibi
kontrollü salim preparasyonlari olabilir. Bu formülasyonlar Japon Farmakopesinde
açiklanan yöntem gibi iyi bilinen yöntemlere göre üretilebilir.
Oral uygulama sivilari örnegin, genellikle kullanilan sulandiricidaki etken maddeyi
(örnegin saflastirilmis su, etanol ve bunun bir karisimi) çözerek, süspanse ederek veya
emülsifiye ederek üretilir. Sivilar bir islatma ajani, bir süspanse etme ajani, emülgatör,
bir tatlandirici ajan, bir aroma, bir koruyucu, bir tamponlama ajani de içerebilir.
Oral uygulamaya yönelik kati maddeler klasik yöntemlere göre örnegin, etken madde
bir tasiyici (örnegin Iaktoz, manitol, glükoz, mikrokristalin selüloz ve nisasta), bir
baglayici (örnegin hidroksipropil selüloz, polivinilpirolidon ve magnezyum
alüminometasilikat), bir dagitici (örnegin kalsiyum karboksimetil selüloz), bir yaglayici
(örnegin magnezyum stearat), bir stabilizör, bir solüsyon adjuvani (glutamik asit,
aspartik asit) ile karistirarak formüle edilir. Kati maddeler istenirse, bir kaplama ajani ile
(örnegin sükroz, jelatin, hidroksipropil selüloz ve hidroksipropil metilselüloz fitalat)
kaplanabilir ve iki veya daha fazla katman ile kaplanabilir.
Parenteral formülasyonlar olarak topikal formülasyonlar iyi bilinen yöntemlere veya
klasik formülasyonlara göre üretilir. Örnegin, merhemler etken maddenin bir baz içinde
ögütülmesi veya eritilmesi yoluyla üretilir. Merhemlere yönelik baz bu iyi bilinen veya
klasik olarak kullanilanlar arasindan seçilir. Asagidakilerden biri veya daha fazlasi
örnegin, tek basina veya kombinasyonla kullanilabilir: daha yüksek yag asidi veya daha
yüksek yag asidi esteri (örnegin adipik asit, miristik asit, palmitik asit, stearik asit, oleik
asit, adipat ester, miristat ester, palmitat ester, stearat ester ve oleat ester), bir mum
(örnegin bal mumu, balina mumu ve seresin), bir sürfaktan (örnegin polioksietilen alkil
eter fosfat esterler), daha yüksek bir alkol (örnegin setanol, stearil alkol ve setostearil
alkol), bir silikon yagi (örnegin dimetilpolisiloksan), bir hidrokarbon (örnegin hidrofilik
petrolatum, beyaz petrolatum, saflastirilmis Ianolin ve sivi parafin), bir glikol (örnegin
etilen glikol, dietilen glikol, propilen glikol, polietilen glikol ve makrogol), bitkisel yag
(örnegin kastor yagi, zeytin yagi, susam yagi ve terebentin yagi), hayvansal yag
(örnegin mink yagi, yumurta sarisi yagi, skualen ve skualen), su, bir emme iyilestirici
araç ve bir kizariklik önleyici araç içerebilir. Formülasyonlar bir nemlendirici, bir
koruyucu, bir stabilizör, bir antioksidan, bir aroma verici ajan da içerebilir.
Parenteral formülasyonlar olarak üretilen enjeksiyonlar kullanimdan sonra bir solvent
içinde çözülen veya süspanse edilen solüsyonlari, süspansiyonlari, emülgatörleri ve
kati madde enjeksiyonlarini içerir. Enjeksiyonlar örnegin, etken maddeyi bir solvent
içinde çözerek, süspanse ederek veya emülsifiye ederek kullanilir. Kullanilan solvent,
örnegin, enjeksiyonlara yönelik distile su, maden tuzu, bitkisel yag, propilen glikol,
polietilen glikol, etanol veya bunun bir kombinasyonu gibi alkollerdir. Enjeksiyonlar bir
stabilizör, bir solüsyon adjuvani (örnegin glutamik asit, aspartik asit ve Polysolvate
80®), bir süspanse etme ajani, bir emülgatör ajani, bir yumusatma ajani, bir
tamponlama ajani, bir koruyucu da içerebilir. Alternatif olarak, aseptik kati madde
formülasyonlari, örnegin, enjeksiyona yönelik sterilize veya aseptik su içinde
kullanimdan önce çözülebilen dondurularak kurutulmus formülasyonlar üretilir.
Yukarida açiklanan amaçlara yönelik olarak, mevcut bilesik veya mevcut bilesigin bir
konkomitant ajan ve baska bir ilaç, genellikle oral veya parenteral formda sistemik veya
lokal olarak uygulanir. Dozaj yas, agirlik, semptomlar, terapötik etki, uygulama yolu,
tedavi süresine göre farklilik gösterebilir ve genellikle bir yetiskine oral yolla tek bir
dozda 1 ng ila 1000 mg arasinda günde bir veya birkaç defa veya bir yetiskine
parenteral tek bir dozda 0.1 ng ila 10 mg arasinda günde bir veya birkaç defa veya
damar içinden sürekli olarak günlük 1 saat veya 24 saat uygulanir. Dozaj, yukarida
açiklandigi gibi, süphesiz çesitli kosullara göre farklilik gösterebilir ve bu yüzden bazi
durumlarda yukarida açiklanan araliktan daha az dozaj yeterli olabilir ve bazi
durumlarda yukarida açiklanan araliktan daha fazla dozaj gerekli olabilir.
Örnekler
Mevcut bulus bundan sonra Örnekler yoluyla detayli olarak açiklanir.
Kromatografi separasyonu ve TLC bölümlerinde parantez içinde açiklanan solventler
kullanilan elüsyon solventlerini veya gelistirme solventlerini belirtir ve oranlar hacim
oranlari ile temsil edilir.
NMR'nin bölümlerinde parantez içinde açiklanan solventler ölçümler için kullanilan
solventleri belirtir.
Bilesikler mevcut spesifikasyonda, IUPAC kurallari veya IUPAC nomenklatür sistemine
göre belirten, Advanced Chemistry Development`in bir bilgisayar programi,
ACDIName® kullanilarak belirtilir.
Örnek 1: Benzil 2-metiI-2-{3-[3-nitro-5-(triflorometil)fenoksi]fenil}pr0panoat
Argon atmosferi altinda 1,3-dinitro-5-(triflorometiI)benzen (1.52 9) ve benzil 2-(3-
hidroksifenil)-2-metilpropanoat ( (10
mL) eklenmistir ve karisima potasyum sülfat (2.04 9) eklenmistir, akabinde 90°C'de 9
saat karistirilmistir. Reaksiyon solüsyonu oda sicakligina sogutulmustur, etil asetat ile
seyreltilmistir, su ile iki kez yikanmistir, tuzlu su ile yikanmistir ve anhidröz magnezyum
sülfat üzerinde kurutulmustur ve solvent damitilmistir. Ortaya çikan kalinti, asagidaki
fiziksel özelliklere sahip basliktaki bilesigi (2.82 9) vermek üzere silika jel kromatografisi
(hekzanzetil asetat = 100:0 -› 0:100) ile saflastirilmistir.
Örnek 2: Benzil 2-{3-[3-amino-5-(triflorometil)fenoksi]fenil}-2-metilpropanoat
Örnek 1'de üretilen bilesik (2.82 9), oda sicakliginda etanol (50 mL) ve su (10 mL)
içinde çözülmüstür, bu solüsyona amonyum klorid (327 mg) eklenmistir. Akabinde
demir (1.88 9), 90°C'de 2 saat karistirilan reaksiyon solüsyonuna eklenmistir.
Reaksiyon solüsyonu oda sicakligina sogutulmustur ve selit ile filtrelenmistir. Ortaya
çikan filtrat konsantre edilmistir, etil asetat ile seyreltilmistir, su ile yikanmistir, tuzlu su
ile yikanmistir ve anhidröz magnezyum sülfat üzerinde kurutulmustur ve solvent
damitilmistir. Asagidaki fiziksel özelliklere sahip basliktaki bilesik (2.63 9) bu sekilde
elde edilmistir.
Örnek 3: Benzil 2-metil-2-{3-[3-{[(2,2,2-trikloroetoksi)karbonil]amino}-5-
(triflorometiI)fenoksi]feniI}propanoat
Örnek 2`de üretilen bilesik (2.63 9), oda sicakliginda etil asetat (50 mL) içinde
çözülmüstür. Sodyum hidrojen karbonat (2.57 9) solüsyona eklenmistir ve karistirilirken
2,2,2-trikl0r0etil kloroformat (, damlatilarak eklenmistir. Reaksiyon solüsyonu
4 saat karistirilmistir, su ile iki kez yikanmistir, tuzlu su ile yikanmistir ve anhidröz
magnezyum sülfat üzerinde kurutulmustur ve solvent damitilmistir. Ortaya çikan kalinti,
asagidaki fiziksel özelliklere sahip basliktaki bilesigi (3.33 9) vermek üzere silika jel
kromatografisi (hekzan:etil asetat = 10020 -› 0:100) ile saflastirilmistir.
Örnek 4: 3-siklohekzil-3-pirolidinol
Alevde kurutulmus üç boyunlu bir balona Iantan klorid bis(lityum klorid) (LaCI3-2LICI)
eklenmistir ve argon atmosferi altinda karisim oda sicakliginda 1 saat karistirilmistir.
O°Ctde tetrahidrofuran (TH F) (10 mL) içindeki benzil 3-0kso-1-pirolidin karboksilat (5.00
9) solüsyonu, akabinde kademeli olarak isitilan ve oda sicakliginda bir gece karistirilan
reaksiyon solüsyonuna damlatilarak eklenmistir. Reaksiyon solüsyonuna %10 asetik
asit ( eklenmistir ve 15 dakika karistirilmistir. Organik katman ayrilmistir ve
solvent damitilmistir. Ortaya çikan kalinti, silika jel kromatografisi (hekzan : etil asetat =
9:1 -› 0:100) ile kismen saflastirilmistir ve solventin damitilmasindan sonra metanol
(50 mL) ve etil asetat (50 mL) ile seyreltilmistir. Seyreltilmis solüsyona %5 paladyum-
karbon (100 mg) eklenmistir ve hidrojen atmosferi altinda oda sicakliginda 2 saat
karistirilmistir. Solüsyon selit ile filtrelenmistir ve solvent, 1.40 9 primer kristal ve 2.0 9
kalinti olarak asagidaki fiziksel özelliklere sahip basliktaki bilesigi vermek üzere
damitilmistir.
Örnek 5: 2-{3-[3-{[(3-siklohekzil-S-hidroksi-1-pirolidinil)karbonil]amin o}-5-
(triflorometil)fenoksi]feniI}-2-metilpropanoik asit
ßi 3 c;
6› `/oi-i
Örnek 3'te üretilen bilesik (
içine eklenmistir ve mikrodalga reaktöründe (CEM Corporation, DISCOVER)
mikrodalga isinlamasi altinda 90°C`de 15 dakika karistirilmistir. Reaksiyon solüsyonu
oda sicakligina sogutulmustur, etil asetat ile seyreltilmistir, su ile iki kez yikanmistir,
tuzlu su ile yikanmistir ve anhidröz magnezyum sülfat üzerinde kurutulmustur ve
solvent damitilmistir. Ortaya çikan kalinti, silika jel kromatografisi (hekzan : etil asetat =
921 -› 0:100) ile kismen saflastirilmistir ve solventin damitilmasindan sonra metanol (5
mL) ve etil asetat (5 mL) ile seyreltilmistir. Solüsyona %5 paladyum-karbon (10 mg)
eklenmistir ve hidrojen atmosferi altinda oda sicakliginda 2 saat karistirilmistir.
Solüsyon selit ile filtrelenmistir ve solvent, asagidaki fiziksel özelliklere sahip basliktaki
bilesigi (199 mg) vermek üzere damitilmistir.
TLC: Rf 0.33 (diklorometanzmetanol = 10:1);
Ornek 5 (1) ila 5 (7)
Asagidaki Örnek bilesikleri, benzil 2-(3-hidroksifeniI)-2-metilpropanoat veya alternatif
olarak bir fenol derivesi ve Örnek 4'te üretilen bilesik veya alternatif olarak ilgili bir
piperidin derivesi kullanilarak Örnek 1 -› Örnek 2 -› Örnek 3 -› Örnek 5 ile ayni
amaçlari olan proseslerin gerçeklestirilmesi yoluyla elde edilmistir.
Örnek 5 (1):4-siklopentil-4-hidroksi-N-[3-{4-[(metilsülfoniI)karbamoil]fenoksi}-5-
(triflorometil)fenil]-1-piperidin karboksamid
1.35.
Örnek 5 (2): 4-siklopentil-N-[3-{4-[(etilsülfoniI)karbamoil]fenoksi}-5-
(triflorometil)fenil]-4-hidroksi-1-piperidin karboksamid
TLC: Rf 0.26 (diklorometan : metanol = 10:1):
Örnek 5 (3):1-{4-[3-{[(3-siklohekziI-3-hidroksi-1-pirolidiniI)karboniI]amin o}-5-
(triflorometil)fenoksi]feniI)siklopropankarboksilik asit
TLC: Rf 0.56 (diklorometan : metanol = 10:1);
(triflorometil)fenoksi]fenoksi}-2-metilpropanoik asit
TLC: Rf 0.17 (diklorometan : metanol = 10:1):
1.13.
Örnek 5 (5):1-{4-[3-{[(3-siklohekziI-3-hidroksi-1-pirolidinil)karbonil]amin o}-5-
(triflorometil)fenoksi]fenoksi}sikIopropankarboksilik asit
TLC: Rf 0.11 (diklorometan : metanol = 10:1);
Örnek 5 (6):1-{4-[3-{[(3-siklohekziI-3-hidroksi-1-pirolidinil)karbonil]amin o}-5-
(triflorometil)fenoksi]feniI}siklobütankarboksilik asit
TLC: Rf 0.69 (kloroform : metanol = 5:1);
(triflorometil)fenoksi]feniI}siklopentankarboksilik asit
TLC: Rf 0.46 (kloroform : metanol = 5:1);
Örnek 6: (+)-1-{4-[3-{[(3-siklohekzil-3-hidroksi-1-pirolidinil)karbonil] amino}-5-
(triflorometil)fenoksi]feniI}siklobütankarboksilik asit ve (-)-1-{4-[3-{[(3-siklohekzil-
3-hidroksi-1-pirolidinil)karbonil] amino}-5-
(triflorometil)fenoksi]feniI}siklobütankarboksilik asit
Örnek 5 (6)`da üretilen bilesik, HPLC (kullanilan kolon: Daicel Corporation,
CHIRALPAK AD (4.6 mm x 250 mm); gelistirme solventi: hekzanzetanol:trifloroasetik
asit = 50:50:1; akis orani: 1 mL/dakika) ile optik ayristirma islemine tabi tutulmustur.
Yukaridaki optik ayristirma kosulari altinda Örnek 5 (6)'daki optik olarak aktif maddeler,
sirasiyla birinci pikte (retansiyon süresi: yaklasik 4.5 dakika) ve ikinci pikte (retansiyon
süresi: yaklasik 5.5 dakika) elde edilmistir. Birinci pikte elde edilen bilesigin optik
rotasyonu asagidaki gibidir.
Bu nedenle birinci pikteki bilesigin, Örnek 5 (6)'daki dekstrorotator optik madde oldugu
ve ikinci pikteki bilesigin, Örnek 5 (6)'daki Ievorotator optik madde oldugu bulunmustur.
(triflorometil)fenoksi]feniI}-2-metilpropanoik asit ve (-)-2-{3-[3-{[(3-siklohekziI-3-
hidroksi-1-pirolidinil)karbonil]amino}-5-(triflorometiI)fenoksi]fenil}-2-
metilpropanoik asit
Örnek 5'te üretilen bilesikten dekstrorotator ve Ievorotator optik maddeler, Örnek 6'da
açiklanan optik ayristirma kosullari altinda elde edilmistir.
Örnek 7: (Reference) 3-{[(4-hidroksi-4-izobütil-1-piperidinil)karbonil]amino}-5-(tri
florometil)benzoik asit
Asagidaki fiziksel özelliklere sahip basliktaki bilesik (957 mg), 4-izobütil-4-piperidin0l
kullanilarak Örnek 5 ile ayni amaca sahip prosesin gerçeklestirilmesi ile elde edilmistir
ve bilesik, Örnek 1'de üretilen bilesik yerine metil 3-nitro-5-(trifl0rometil)benzoat (5.3 9)
kullanilarak Örnek 2 -› Örnek 3 ile ayni amaca sahip proseslerin gerçeklestirilmesi ile
elde edilmistir.
Örnek 8: 2-(4-{[3-{[(4-hidroksi-4-izobütil-1-piperidinil)karbonil]amino} -5-
(triflorometil)benzoil]oksi}feniI)-2-metiIpropanoik asit
Örnek 7'de üretilen bilesik (-2-
metilpropanoat (125 mg) içinde çözülmüstü r, buna 1-etiI-3-(3-
dimetilaminopropil)karb0diimid hidroklorid (EDC) (111 mg), 1-hidr0ksibenzotriazol
monohidrat (HOBt) (78.2 mg) ve diizopropiletilamin ( eklenmistir ve oda
sicakliginda bir gece karistirilmistir. Reaksiyon solüsyonu etil asetat ile seyreltilmistir,
su ile iki kez yikanmistir, tuzlu su ile yikanmistir ve anhidröz magnezyum sülfat
üzerinde kurutulmustur ve solvent damitilmistir. Ortaya çikan kalinti, silika jel
kromatografisi (hekzan : etil asetat = 9:1 -› 0:100) ile kismen saflastirilmistir, solvent
damitilmistir ve solüsyon, metanol (1 mL) ve etil asetat (1 mL) ile seyreltilmistir.
Solüsyona %5 paladyum-karbon (10 mg) eklenmistir ve hidrojen atmosferi altinda oda
sicakliginda 2 saat karistirilmistir. Reaksiyon solüsyonu selit ile filtrelenmistir ve
solvent, asagidaki fiziksel özelliklere sahip basliktaki bilesigi (27.5 mg) vermek üzere
damitilmistir.
TLC: Rf 0.68 (kloroform : metanol = 5:1);
Örnek 9: 1-{4-[3-kloro-5-({[4-(4-florofenil)-4-hidroksi-1-piperidinil
Asagidaki fiziksel özelliklere sahip basliktaki bilesik, 1,3-dinitro-5-kl0r0benzen, benzil 2-
(3-hidroksifenil)-2-metilpropan0at yerine ilgili fenol derivesi ve Örnek 4*te üretilen bilesik
yerine ilgili bir piperidin derivesi kullanilarak Örnek 1 -› Örnek 2 -› Örnek 3 -› Örnek 5
ile ayni amaca sahip proseslerin gerçeklestirilmesi ile elde edilmistir.
TLC: Rf 0.14 (kloroform : metanol = 9:1);
Örnek 10: 2-[4-(3-floro-5-{[(4-hidroksi-4-izobütiI-1-
piperidiniI)karbonil]amino}fenoksi)fenil]-2-metilpropanoik asit
Asagidaki fiziksel özelliklere sahip basliktaki bilesik, 1,3-dinitr0-5-fl0r0benzen, benzil 2-
(4-hidroksifenil)-2-metilpr0pan0at ve Örnek 4'te üretilen bilesik yerine ilgili piperidin
derivesi kullanilarak Örnek 1 -› Örnek 2 -› Örnek 3 -› Örnek 5 ile ayni amaçlara sahip
proseslerin gerçeklestirilmesi yoluyla elde edilmistir.
TLC: Rf 0.49 (kloroform : metanol = 9:1);
Mevcut bilesiklerin etkileri bundan sonra gösterilen deneysel yöntemlere göre biyolojik
deneysel örnek ve fiziksel deneysel örnek olarak dogrulanmistir.
Biyolojik Deneysel Örnek 1: Hücre içi kalsiyumu iyon konsantrasyonundaki
degisimi izleyerek S antagonistik aktivitesinin degerlendirilmesi
Insan S hücreleri, %10
fetal bovin serumu (FBS), bir antibiyotik/antifungal ajani ve G418 içeren bir Ham F12
ortaminda üretilmistir. Fare S genini asiri üreten CHO hücreleri, %10 FBS,
penisilin/streptomisin ve blastisidin S içeren bir Ham F12 ortaminda üretilmistir. Üretilen
hücreler 37°Cide 60 dakika boyunca (5 uM) [PES (%10), HEPES tampon (20 mM, pH
7.2 ila 7.5 içeren bir Ham F12 ortami) ve probenesid (] içeren bir Fura2-AM
solüsyonunda inkübe edilmistir. Hücreler HEPES tampon (20 mM, pH 7.2 ila 7.5) ve
probenesid ( içeren bir Hanks dengeli tuz ile iki defa yikanmistir ve ayni
solüsyona batirilmistir. Floresan bazli ilaç tarama sistemine bir plaka monte edilmistir
ve hücre içi kalsiyum iyon konsantrasyonu stimülasyon olmadan 30 saniye boyunca
ölçülmüstür. Bir test maddesi (insan Sin geninin nihai konsantrasyonu: 0.25 nM ila 25
(M ve fare 81P2 geninin nihai konsantrasyonu: veya dimetil
sülfoksid (DMSO) solüsyonu eklenmistir ve 3 dakika sonra SiP (nihai konsantrasyon:
veya eklenmistir ve SlP eklenmeden önce ve eklenmistirkten sonra hücre
içi kalsiyum iyon konsantrasyonundaki artis 3 saniyelik araliklarla ölçülmüstür
(eksitasyon dalga boyu: 340 nm ve 380 nm, floresan dalga boyu: 540 nm).
S olarak
hesaplanmistir, burada A bir test maddesi olmayan DMSO ile eklenmis haznelerde
S1P'nin eklenmesinden sonra bir pik degeri olan kontrol degeridir (nihai konsantrasyon:
veya ve B, test maddesi ile tedavi edilmis hücrelerde S1P'nin
eklenmesinden sonra artirilmis miktaridir:
Baskilama (%) = [i'A-Bi/A] x 100
hesaplanmistir.
bilesik A olarak refere edilecektir) ve Örnek 1(85)'de (bundan böyle karsilastirmali
bilesik B olarak refere edilecektir) açiklanan karsilastirmali bilesikler kullanilmistir.
Karsilastirmali bilesiklerin yapisal formülleri sirasiyla asagida gösterilir.
Karsilastirmali bilesik A
ö IN# kek-F
Karsilastirmali bilesik B
Mevcut bilesiklerin ve karsilastirmali bilesiklerin insan ve siçan S
antagonistik aktiviteleri asagidaki Tablo 1'de gösterilmistir.
S1P2 antagonistik aktivitesi IC50 (nM)
Bilesik _
Karsilastirmali bilesik A 1600 72
Karsilastirmali bilesik B 1200 27
Sonuç olarak, mevcut bilesiklerin karsilastirmali bilesikler ile karsilastirildiginda insan
S1P2 antagonistik aktivitesini önemli ölçüde iyilestirdigi sonucuna ulasilmistir. Ayrica,
mevcut bilesikler, türler, baska bir deyisle insan ve fare arasinda arasinda S1P2
antagonistik aktivitedeki farki iyilestirmistir ve bu yüzden fare patolojik modeller ila
insanda elde edilen verimliligin ekstrapolasyonunu olanakli kilabilir.
Fiziksel Deneysel Örnek 2: Çözünürlük ölçümü
Kalibrasyon egrisi elde etmeye yönelik bir solüsyon, bir test maddesini (10 mmoI/L,
DMSO solüsyon) asetonitrilde sulandirarak ve 0.1, 0.4 ve 2 umol/L degerine ayarlamak
üzere asetonitril içerigine bir dahili standart madde (varfarin) ekleyerek hazirlanmistir.
Japon Farmokopsisinde (1000 mL'ye ayarlamak üzere 0.2 mol/L potasyum dihidrojen
fostaf reaktif solüsyonun 250 mL'sine ve 0.2 mol/L sodyum hidroksid reaktif solüsyonun
tanimlanmis ikinci
solüsyonun , bir test maddesinin 5 uL'sini ekleyerek, oda
sicakliginda 5 saat karistirarak, elde edilen solüsyonu vakum filtrasyon için filtreli bir
plakaya aktararak, filtratin 20 uL'sini asetonitril ile sulandirarak ve dahili standarda
astonitril içerigi ekleyerek bir numune solüsyon hazirlanmistir. Kalibrasyon egrisi elde
etmeye yönelik solüsyon ve numune solüsyon (her biri 5 uL) kantifikasyona yönelik
olarak (kantifikasyon araligi: 0.1 ila 2 umoI/L) LC-MS/MS'ye (Discovery Max from
Thermo Scientific) enjekte edilmistir. Çözünürlük, kantifiye degeri 50 ile çarparak
hesaplanmistir. Kantifiye deger kantifikasyon araliginin disinda oldugunda, çözünürlük
< 5 umoI/L veya 100 umoI/L olarak ifade edilmistir.
Mevcut bilesiklerin ve karsilastirmali bilesiklerin çözünürlügü asagidaki Tablo 2'de
gösterilir.
Bilesik Çözünürlük (pmoI/L)
Karsilastirmali bilesik A < 5
Karsilastirmali bilesik B < 5
Sonuç olarak, mevcut bilesiklerin, karsilastirmali bilesiklerden daha üstün çözünürlüge
sahip oldugu belirlenmistir.
Formülasyon Örnegi 1
Asagidaki bilesenler karistirilir ve akabinde, tablet basina sirasiyla 10 mg aktif bilesen
içeren 10,000 tablet elde etmek üzere klasik yönteme göre tabletler yapmak amaciyla
sikistirilir.
1-{4-[3-{[(3-siklohekziI-3-hidroksi-1-piroIidinil)karbonil]amin o}-5-
(triflorometil)fenoksi]feniI}sikl0pentankarboksilik
- Karboksimetilselüloz kalsiyum 20 g
. Magnezyum Stearat 10 g
Formülasyon Örnegi 2
Asagidaki bilesenler, klasik yönteme göre karistirilir, akabinde toz uzaklastirma
filtresinden filtrelenir, ampul basina 5 ml olarak bölünür, ampul basina sirasiyla 20 mg
aktif bilesen içeren 10,000 ampul elde etmek üzere otoklavda isitma ile sterilize edilir.
1-{4-[3-{[(3-siklohekziI-3-hidroksi-1-pirolidinil)karbonil]amin o}-5-
(triflorometil)fenoksi]feniI}siklopentankarboksilik
0 Mannitol 20 g
. Damitilmis su 50 L
mÜSTRIYEi. UYGULANABILIRLIK
Mevcut bilesik yüksek S1P2 antagonistik aktiviteye sahiptir ve bu yüzden vasküler
daralma ve fibrosizden kaynaklanan hastaliklar gibi S1P2-aracili hastaliklarin
tedavisine yönelik olarak yararlidir.
Claims (1)
- ISTEMLER Genel formül (I) ile temsil edilen bir bilesik, bir tuzu, solvati veya N-oksididir: ile sübstitüe edilebilen C2-8 alkinil grubu veya (4) C1-4 alkil grubu, C1-4 haloalkil grubu, Ci-4 alkoksi grubu ve halojen atomundan olusan gruptan seçilen 1 ila 5 sübstitüent ile sübstitüe edilebilen C3-7 karbosikli temsil eder; R“, (1) halojen atomu, (2) OR22 (bu grupta R”, (1) bir hidrojen atomu, (2) C1-4 alkil grubu veya (3) C1-4 haloalkil grubunu temsil eder), (3) -NR23R24 (bu grupta R23 ve R24 sirasiyla ve bagimsiz olarak (1) bir hidrojen atomu veya (2) Ci-4 alkil grubunu temsil eder) veya (4) bir okso grubunu temsil eder; R2, (1) bir hidrojen atomu, (2) C1-4 alkil grubu veya (3) C1-4 haloalkil grubunu temsil eder; R3, (1) halojen atomu, (2) C1-4 alkil grubu, (3) Ci-4 haloalkil grubu, (4) Ci-4 alkoksi grubu, (5) hidroksi grubu, (6) -L-CONR6R7, (7) -L-SOzR8 veya (8) -L- COORg'u temsil eder; R4, (1), halojen atomu, (2) C1-4 alkil grubu veya (3) C1-4 haloalkil grubunu temsil eder; L, (1) bir bag, (2) asagidaki formüle ile temsil edilen bir grup: burada A, (1) bir bag veya (2) bir oksijen atomunu temsil eder; R12 ve R13 sirasiyla ve bagimsiz olarak (1) hidrojen atomu, (2) Ci-4 alkil grubu, (3) hidroksi grubu veya (4) NHz'yi temsil eder veya (5) R12 ve R”, eklendikleri karbon atomu ile birlikte 03-? karbosikl olusturabilir ve sag taraftaki ok, -CONR6R7, - SOzR8 veya -COORQ'a baglanir, veya (6) C1-4 alkil grubu ile sübstitüe edilebilen bir nitrojen atomunu temsil Rs ve R7 sirasiyla ve bagimsiz olarak (1) bir hidrojen atomu, (2) C1-4 alkil SOzNR -802R17`yi temsil eder veya R6 ve R7, eklendikleri nitrojen atomu ile birlikte, bir hidroksi grubu ile sübstitüe edilebilen 4 ila 7 üyeli nitrojen içeren doymus bir heterosikli olusturabilir; R9, (1) bir hidrojen atomu veya (2) C1-8 alkil grubunu temsil eder; R1° ve R11 sirasiyla ve bagimsiz olarak (1) bir hidrojen atomu, (2) C1-4 alkil grubu, (3) -CONR -802R17”yi temsil halka 1, 5 ila 7 üyeli siklik bir grubu temsil eder; R15 ve R16 sirasiyla ve bagimsiz olarak (1) hidrojen atomu, (2) C1-4 alkil grubu veya (3) 5 ila 7 üyeli siklik bir grubu temsil eder; R”, (1) C1-4 alkil grubu veya (2) 5 ila 7 üyeli siklik bir grubu temsil eder; M1, (1) bir bag, (2) -C(O)-, (3) -O-, (4) -S-, (5) -C(O)O-, (6) -CH2O- veya (7) - C(O)NH-'yi temsil eder; M2, bir halojen atomu veya C1-4 haloalkil grubunu temsil eder; n, 1 ila 2 olan bir tamsayiyi temsil eder; m, 1 ila 2 olan bir tamsayiyi temsil eder; p, 0 ila 5 olan bir tamsayiyi temsil eder; r, 0 ila 4 olan bir tamsayiyi temsil eder; t, 1 ila 4 olan bir tamsayiyi temsil eder; p, 2 veya daha fazla oldugunda birçok R3 grubu ayni veya farkli olabilir; r, 2 veya daha fazla oldugunda birçok R4 grubu ayni veya farkli olabilir ve t, 2 veya daha fazla oldugunda birçok R12 ve R13 grubu sirasiyla ayni veya farkli olabilir. . Istem 1'e göre bilesik, bir tuzu, solvati veya N-oksididir, burada R1, (1) 1 ila 5 R21 grubu ile sübstitüe edilebilen bir C1-8 alkil grubu veya (2) C1-4 alkil grubu, C1-4 haloalkil grubu, C1-4 alkoksi grubu ve bir halojen atomundan olusan gruptan seçilen 1 ila 5 sübstitüent ile sübstitüe edilebilen C3-7 karbosikldir. 3. Istem 1 veya ?ye göre bilesik, bir tuzu, solvati veya N-oksididir, burada M1, (1) - 0- veya (2) -C(O)O-'dur. 4. Genel formül (H) ile temsil edilen istem 1'e göre bilesik, bir tuzu, solvati veya N-oksididir: burada R”, (1) 1 ila 5 R21 grubu ile sübstitüe edilebilen 01-8 alkil grubu veya (2) C1-4 alkil grubu, C1-4 haloalkil grubu, C1-4 alkoksi grubu ve bir halojen atomundan olusan gruptan seçilen 1 ila 5 sübstitüent ile sübstitüe edilebilen 03- 7 karbosikli temsil eder. 5. Istem 4'e göre bilesik, bir tuzu, solvati veya N-oksididir, burada R2, bir hidrojen atomudur. 6. Istem 4 veya 5'e göre bilesik, bir tuzu, solvati veya N-oksididir, burada halka 1, (1) benzen, (2) siklohekzan veya (3) piridin halkasidir. 7. Asagidakiler olan istem 1'e göre bilesik, bir tuzu, solvati veya N-oksididir: 2-{3-[3-{[(3-siklohekziI-3-hidroksi-1-pirolidinil)karb0nil]amino}-5- (triflorometil)fen0ksi]feniI}-2-metilpropanoik asit, 4-siklopentiI-4-hidroksi-N-[3-{4-[(metilsülfonil)karbam0il]fenoksi}-5- (triflorometil)fenil]-1-piperidin karboksamid, 4-sikl0pentiI-N-[3-{4-[(etilsülfonil)karbamoil]fen0ksi}-5-(triflorometil)fenil]-4- hidroksi-1-piperidin karboksamid, 1 -{4-[3-{[(3-siklohekzil-3-hidroksi-1-pirolidinil)karbonil]amino}-5- (triflorometil)fenoksi]fenil}siklopropankarboksilik asit, 2-{4-[3-{[(3-siklohekziI-3-hidroksi-1-pirolidiniI)karb0niI]amino}-5- (triflorometil)fenoksi]fenoksi}-2-metilpropanoik asit, 1 -{4-[3-{[(3-sikl0hekzil-3-hidroksi-1-pirolidinil)karbonil]amino}-5- (triflorometil)fenoksi]fen0ksi}siklopropankarboksilik asit, 1 -{4-[3-{[(3-siklohekziI-3-hidroksi-1-pirolidinil)karb0nil]amin0}-5- (triflorometil)fen0ksi]fenil}sikl0bütankarboksilik asit, 1 -{4-[3-{[(3-sikl0hekziI-3-hidroksi-1-pirolidiniI)karboniI]amin0}-5- (triflorometil)fen0ksi]fenil}siklopentankarboksilik asit, 2-(4-{[3-{[(4-hidroksi-4-izobütiI-1-piperidinil)karb0nil]amin0}-5- (triflorometil)benzoil]oksi}feniI)-2-metiIpropanoik asit, piperidinil]karb0niI}amin0)fenoksi]fenoksi}sikl0propankarboksilik asit, 2-metilpropan0ik asit, (+)-1-{4-[3-{[(3-siklohekzil-3-hidroksi-1-pirolidinil)karb0nil]amino}-5-(triflorometil) fenoksi]fenil}sikl0bütankarboksilik asit, (-)-1-{4-[3-{[(3-siklohekzil-S-hidroksi-1-pirolidinil)karbonil]amino}-5-(triflorometil) fenoksi]fenil}siklobütankarboksilik asit, (+)-2-{3-[3-{[(3-siklohekzil-S-hidroksi-1-pirolidiriil)karb0nil]amino}-5-(triflorometil) fenoksi]feniI}-2-metilpropanoik asit veya (-)-2-{3-[3-{[(3-siklohekziI-3-hidroksi-1-pirolidinil)karboniI]amino}-5-(trifl0rometil) fenoksi]feniI}-2-metilpropanoik asit. 4-sikl0pentiI-4-hidroksi-N-[3-{4-[(metilsülfonil)karbam0il]fenoksi}-5- (triflorometil)feniI]-1-piperidin karboksamid veya 1-{4-[3-{[(3-siklohekziI-S- hidroksi-1-piroIidiniI)karboniI]amino}-5- (triflorometil)fenoksi]fenil}siklopentankarboksilik asit olan istem 4'e göre bilesik, bir tuzu, solvati veya N-oksididir. Istem 1'e göre genel formül (I) ile temsil edilen bilesigi, tuzunu, solvatini veya N- oksidini içeren farmasötik bir bilesimdir. 10.Vasküler daralma, fibrozis, respiratuar hastalik, arteriyoskleroz, periferik arter tikanikligi hastaligi, retinopati, glokom, yasa bagli maküler dejenerasyon, nefrit, diyabet, diyabetik komplikasyon, dislipidemi, hepatit, hepatik siroz, hepatik yetmezlik, nöropati, romatoid artrit, yara, agri, ürtiker, sistemik Iupus eritematozus (SLE) ve kanserden kaynaklanan bir hastaliktan seçilen S1P2 aracili bir hastaligin profilaksisinde ve/veya terapisinde kullanilmaya yönelik istem ya göre farmasötik bilesimdir. istem 10'a göre farmasötik bilesim olup, özelligi vasküler daralmadan kaynaklanan hastaligin, serebral vazospastik hastalik, kardiyak vazospastik hastalik, koroner vazospastik hastalik, hipertansiyon, pulmoner hipertansiyon, miyokard enfarktüsü, anjina, aritmi, portal hipertansiyon, varis, assit, splenomegali, hepatik ensefalopati veya iskemi-reperfüzyon hasari olmasidir. Istem 11'e göre kullanima yönelik farmasötik bilesim olup, özelligi farmasötik bilesimin, günde bir kez uygulanmasidir. istem 11 veya 12'ye göre kullanima yönelik farmasötik bilesim olup, özelligi farmasötik bilesimin, portal hipertansiyon ile iliskili özpofageal varisten kaynaklanan primer veya sekonder kanamanin profilaksisinde kullanima yönelik olmasidir. 14.Vasküler daralma, fibrozis, respiratuar hastalik, arteriyoskleroz, periferik arter tikanikligi hastaligi, retinopati, glokom, yasa bagli maküler dejenerasyon, nefrit, diyabet, diyabetik komplikasyon, dislipidemi, hepatit, hepatik siroz, hepatik yetmezlik, nöropati, romatoid artrit, yara, agri, ürtiker, sistemik Iupus eritematozus (SLE) ve kanserden kaynaklanan bir hastaliktan seçilen 81P2 aracili bir hastaligin profilaksisinde ve/veya terapisinde kullanilmaya yönelik istem 1'e göre genel formül (l) ile temsil edilen bilesik, tuzu, solvati veya N- oksididir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013063304 | 2013-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201808812T4 true TR201808812T4 (tr) | 2018-07-23 |
Family
ID=51624129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2018/08812T TR201808812T4 (tr) | 2013-03-26 | 2014-03-25 | Fenil derivesi. |
Country Status (24)
Country | Link |
---|---|
US (1) | US9676719B2 (tr) |
EP (1) | EP2980072B1 (tr) |
JP (1) | JP6245255B2 (tr) |
KR (1) | KR20150135281A (tr) |
CN (1) | CN105189454B (tr) |
AU (1) | AU2014245879B2 (tr) |
BR (1) | BR112015024897A2 (tr) |
CA (1) | CA2907964A1 (tr) |
DK (1) | DK2980072T3 (tr) |
ES (1) | ES2671559T3 (tr) |
HK (1) | HK1214588A1 (tr) |
HU (1) | HUE038919T2 (tr) |
MX (1) | MX2015013618A (tr) |
MY (1) | MY183186A (tr) |
NO (1) | NO2980072T3 (tr) |
NZ (1) | NZ712540A (tr) |
PH (1) | PH12015502203B1 (tr) |
PL (1) | PL2980072T3 (tr) |
PT (1) | PT2980072T (tr) |
RU (1) | RU2639875C2 (tr) |
SG (1) | SG11201507983XA (tr) |
TR (1) | TR201808812T4 (tr) |
WO (1) | WO2014157158A1 (tr) |
ZA (1) | ZA201507112B (tr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2689132T3 (es) * | 2011-09-29 | 2018-11-08 | Ono Pharmaceutical Co., Ltd. | Derivado de fenilo |
KR102243426B1 (ko) * | 2013-03-26 | 2021-04-21 | 오노 야꾸힝 고교 가부시키가이샤 | 페닐 유도체를 함유하는 의약 |
US20210038502A1 (en) | 2017-11-08 | 2021-02-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | S1pr2 antagonists for treating diseases involving abnormal immune responses |
WO2021026479A1 (en) * | 2019-08-07 | 2021-02-11 | Stamford, Andrew | Small molecule inhibitors of s1p2 receptor and uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06234797A (ja) | 1993-02-10 | 1994-08-23 | Tsumura & Co | レセプター活性を有する新規ペプチドおよび該ペプチドをコードするdna |
AU2001264313A1 (en) | 2000-06-20 | 2002-01-02 | Japan Tobacco Inc. | Pyrazolopyridine compounds and use thereof as drugs |
EP1522314B1 (en) * | 2002-06-26 | 2014-03-05 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases caused by vascular contraction or dilation |
RU2390519C2 (ru) | 2003-08-29 | 2010-05-27 | Оно Фармасьютикал Ко., Лтд. | Соединение, способное к связыванию с рецептором s1p, и его фармацевтическое применение |
CN1590378A (zh) | 2003-08-29 | 2005-03-09 | 中国科学院上海药物研究所 | 一类喹喔啉衍生物及其制备方法和用途 |
BRPI0413923A (pt) | 2003-08-29 | 2006-11-07 | Ono Pharmaceutical Co | composto capaz de ligar o receptor de s1p e uso farmacêutico do mesmo |
CN1874991A (zh) * | 2003-08-29 | 2006-12-06 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
EP1698375B1 (en) * | 2003-12-25 | 2014-04-02 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
AU2007245734A1 (en) | 2006-04-27 | 2007-11-08 | Solvay Pharmaceuticals Gmbh | Use of CBX cannabinoid receptor modulators as potassium channel modulators |
US20100216767A1 (en) | 2006-12-22 | 2010-08-26 | Mina Aikawa | Quinazolines for pdk1 inhibition |
US20100121052A1 (en) | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
WO2010133748A1 (en) | 2009-05-18 | 2010-11-25 | Orion Corporation | Protease inhibitors |
CN102812167A (zh) | 2009-12-30 | 2012-12-05 | 阿维拉制药公司 | 蛋白的配体-介导的共价修饰 |
JPWO2011087051A1 (ja) * | 2010-01-14 | 2013-05-20 | 国立大学法人金沢大学 | S1p2受容体アンタゴニストを含む粥状動脈硬化治療薬 |
ES2689132T3 (es) | 2011-09-29 | 2018-11-08 | Ono Pharmaceutical Co., Ltd. | Derivado de fenilo |
-
2014
- 2014-03-25 NO NO14775353A patent/NO2980072T3/no unknown
- 2014-03-25 MY MYPI2015703351A patent/MY183186A/en unknown
- 2014-03-25 WO PCT/JP2014/058211 patent/WO2014157158A1/ja active Application Filing
- 2014-03-25 JP JP2015508522A patent/JP6245255B2/ja not_active Expired - Fee Related
- 2014-03-25 HU HUE14775353A patent/HUE038919T2/hu unknown
- 2014-03-25 SG SG11201507983XA patent/SG11201507983XA/en unknown
- 2014-03-25 EP EP14775353.7A patent/EP2980072B1/en active Active
- 2014-03-25 DK DK14775353.7T patent/DK2980072T3/en active
- 2014-03-25 NZ NZ712540A patent/NZ712540A/en not_active IP Right Cessation
- 2014-03-25 US US14/780,152 patent/US9676719B2/en active Active
- 2014-03-25 AU AU2014245879A patent/AU2014245879B2/en not_active Ceased
- 2014-03-25 KR KR1020157025945A patent/KR20150135281A/ko not_active Application Discontinuation
- 2014-03-25 MX MX2015013618A patent/MX2015013618A/es unknown
- 2014-03-25 PT PT147753537T patent/PT2980072T/pt unknown
- 2014-03-25 TR TR2018/08812T patent/TR201808812T4/tr unknown
- 2014-03-25 CN CN201480017929.3A patent/CN105189454B/zh not_active Expired - Fee Related
- 2014-03-25 ES ES14775353.7T patent/ES2671559T3/es active Active
- 2014-03-25 RU RU2015145460A patent/RU2639875C2/ru not_active IP Right Cessation
- 2014-03-25 PL PL14775353T patent/PL2980072T3/pl unknown
- 2014-03-25 CA CA2907964A patent/CA2907964A1/en not_active Abandoned
- 2014-03-25 BR BR112015024897A patent/BR112015024897A2/pt not_active Application Discontinuation
-
2015
- 2015-09-21 PH PH12015502203A patent/PH12015502203B1/en unknown
- 2015-09-25 ZA ZA2015/07112A patent/ZA201507112B/en unknown
-
2016
- 2016-03-01 HK HK16102336.1A patent/HK1214588A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PT2980072T (pt) | 2018-06-06 |
US9676719B2 (en) | 2017-06-13 |
CA2907964A1 (en) | 2014-10-02 |
DK2980072T3 (en) | 2018-06-14 |
CN105189454A (zh) | 2015-12-23 |
WO2014157158A1 (ja) | 2014-10-02 |
BR112015024897A2 (pt) | 2017-07-18 |
SG11201507983XA (en) | 2015-10-29 |
ZA201507112B (en) | 2018-05-30 |
ES2671559T3 (es) | 2018-06-07 |
EP2980072B1 (en) | 2018-04-25 |
AU2014245879A1 (en) | 2015-10-15 |
KR20150135281A (ko) | 2015-12-02 |
EP2980072A1 (en) | 2016-02-03 |
JP6245255B2 (ja) | 2017-12-13 |
US20160039757A1 (en) | 2016-02-11 |
PH12015502203A1 (en) | 2016-02-01 |
JPWO2014157158A1 (ja) | 2017-02-16 |
NO2980072T3 (tr) | 2018-09-22 |
MY183186A (en) | 2021-02-18 |
AU2014245879B2 (en) | 2017-12-21 |
HUE038919T2 (hu) | 2018-12-28 |
PH12015502203B1 (en) | 2016-02-01 |
MX2015013618A (es) | 2016-02-25 |
RU2015145460A (ru) | 2017-05-02 |
CN105189454B (zh) | 2018-07-13 |
RU2639875C2 (ru) | 2017-12-25 |
HK1214588A1 (zh) | 2016-07-29 |
PL2980072T3 (pl) | 2018-08-31 |
NZ712540A (en) | 2018-06-29 |
EP2980072A4 (en) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2467752A1 (en) | Piperidin-2-one derivative compounds and pharmaceutical composition comprising the same as active ingredient | |
JP6249076B2 (ja) | フェニル誘導体 | |
WO2006051826A1 (ja) | 含窒素複素環化合物およびその医薬用途 | |
WO2005063704A1 (ja) | アゼチジン環化合物およびその医薬 | |
EP2382189A1 (en) | Toluidine sulfonamides and their use | |
TR201808812T4 (tr) | Fenil derivesi. | |
JP6264134B2 (ja) | フェニル誘導体を含有する医薬 | |
NZ622539B2 (en) | Diphenoxyphenyl derivative |